CINXE.COM

<!DOCTYPE html> <html lang="en-US" class="no-js"> <head> <meta charset="UTF-8"> <meta name="SKYPE_TOOLBAR" content="SKYPE_TOOLBAR_PARSER_COMPATIBLE" /> <link rel="profile" href="https://gmpg.org/xfn/11"> <meta name="viewport" content="width=device-width, initial-scale=1"> <script> 'use strict'; (function(html){html.className = html.className.replace(/\bno-js\b/,'js')})(document.documentElement);</script> <meta name='robots' content='noindex, follow' /> <style>img:is([sizes="auto" i], [sizes^="auto," i]) { contain-intrinsic-size: 3000px 1500px }</style>  <title>2023 - Lexaria Bioscience</title> <meta property="og:locale" content="en_US" /> <meta property="og:type" content="website" /> <meta property="og:title" content="2023 - Lexaria Bioscience" /> <meta property="og:url" content="https://lexariabioscience.com/2023/" /> <meta property="og:site_name" content="Lexaria Bioscience" /> <meta name="twitter:card" content="summary_large_image" /> <script type="application/ld+json" class="yoast-schema-graph">{"@context":"https://schema.org","@graph":[{"@type":"CollectionPage","@id":"https://lexariabioscience.com/2023/","url":"https://lexariabioscience.com/2023/","name":"2023 - Lexaria Bioscience","isPartOf":{"@id":"https://lexariabioscience.com/#website"},"breadcrumb":{"@id":"https://lexariabioscience.com/2023/#breadcrumb"},"inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https://lexariabioscience.com/2023/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://lexariabioscience.com/"},{"@type":"ListItem","position":2,"name":"Archives for 2023"}]},{"@type":"WebSite","@id":"https://lexariabioscience.com/#website","url":"https://lexariabioscience.com/","name":"Lexaria Bioscience","description":"","publisher":{"@id":"https://lexariabioscience.com/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https://lexariabioscience.com/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https://lexariabioscience.com/#organization","name":"Lexaria Bioscience","url":"https://lexariabioscience.com/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https://lexariabioscience.com/#/schema/logo/image/","url":"http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png","contentUrl":"http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png","width":418,"height":220,"caption":"Lexaria Bioscience"},"image":{"@id":"https://lexariabioscience.com/#/schema/logo/image/"}}]}</script>  <link rel='dns-prefetch' href='//www.googletagmanager.com' /> <link rel='dns-prefetch' href='//fonts.googleapis.com' /> <link href='//hb.wpmucdn.com' rel='preconnect' /> <link href="https://fonts.googleapis.com" rel='preconnect' /> <link href='//fonts.gstatic.com' crossorigin='' rel='preconnect' /> <link rel="alternate" type="application/rss+xml" title="Lexaria Bioscience » Feed" href="https://lexariabioscience.com/feed/" /> <link rel="alternate" type="application/rss+xml" title="Lexaria Bioscience » Comments Feed" href="https://lexariabioscience.com/comments/feed/" /> <script> /* <![CDATA[ */ window._wpemojiSettings = {"baseUrl":"https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/72x72\/","ext":".png","svgUrl":"https:\/\/s.w.org\/images\/core\/emoji\/15.0.3\/svg\/","svgExt":".svg","source":{"concatemoji":"https:\/\/lexariabioscience.com\/wp-includes\/js\/wp-emoji-release.min.js?ver=6.7.1"}}; /*! This file is auto-generated */ !function(i,n){var o,s,e;function c(e){try{var t={supportTests:e,timestamp:(new Date).valueOf()};sessionStorage.setItem(o,JSON.stringify(t))}catch(e){}}function p(e,t,n){e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(t,0,0);var t=new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data),r=(e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(n,0,0),new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data));return t.every(function(e,t){return e===r[t]})}function u(e,t,n){switch(t){case"flag":return n(e,"\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f","\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f")?!1:!n(e,"\ud83c\uddfa\ud83c\uddf3","\ud83c\uddfa\u200b\ud83c\uddf3")&&!n(e,"\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f","\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f");case"emoji":return!n(e,"\ud83d\udc26\u200d\u2b1b","\ud83d\udc26\u200b\u2b1b")}return!1}function f(e,t,n){var r="undefined"!=typeof WorkerGlobalScope&&self instanceof WorkerGlobalScope?new OffscreenCanvas(300,150):i.createElement("canvas"),a=r.getContext("2d",{willReadFrequently:!0}),o=(a.textBaseline="top",a.font="600 32px Arial",{});return e.forEach(function(e){o[e]=t(a,e,n)}),o}function t(e){var t=i.createElement("script");t.src=e,t.defer=!0,i.head.appendChild(t)}"undefined"!=typeof Promise&&(o="wpEmojiSettingsSupports",s=["flag","emoji"],n.supports={everything:!0,everythingExceptFlag:!0},e=new Promise(function(e){i.addEventListener("DOMContentLoaded",e,{once:!0})}),new Promise(function(t){var n=function(){try{var e=JSON.parse(sessionStorage.getItem(o));if("object"==typeof e&&"number"==typeof e.timestamp&&(new Date).valueOf()<e.timestamp+604800&&"object"==typeof e.supportTests)return e.supportTests}catch(e){}return null}();if(!n){if("undefined"!=typeof Worker&&"undefined"!=typeof OffscreenCanvas&&"undefined"!=typeof URL&&URL.createObjectURL&&"undefined"!=typeof Blob)try{var e="postMessage("+f.toString()+"("+[JSON.stringify(s),u.toString(),p.toString()].join(",")+"));",r=new Blob([e],{type:"text/javascript"}),a=new Worker(URL.createObjectURL(r),{name:"wpTestEmojiSupports"});return void(a.onmessage=function(e){c(n=e.data),a.terminate(),t(n)})}catch(e){}c(n=f(s,u,p))}t(n)}).then(function(e){for(var t in e)n.supports[t]=e[t],n.supports.everything=n.supports.everything&&n.supports[t],"flag"!==t&&(n.supports.everythingExceptFlag=n.supports.everythingExceptFlag&&n.supports[t]);n.supports.everythingExceptFlag=n.supports.everythingExceptFlag&&!n.supports.flag,n.DOMReady=!1,n.readyCallback=function(){n.DOMReady=!0}}).then(function(){return e}).then(function(){var e;n.supports.everything||(n.readyCallback(),(e=n.source||{}).concatemoji?t(e.concatemoji):e.wpemoji&&e.twemoji&&(t(e.twemoji),t(e.wpemoji)))}))}((window,document),window._wpemojiSettings); /* ]]> */ </script> <link rel='stylesheet' id='cnss_font_awesome_css-css' href='https://lexariabioscience.com/wp-content/plugins/easy-social-icons/css/font-awesome/css/all.min.css?ver=5.7.2' media='all' /> <link rel='stylesheet' id='cnss_font_awesome_v4_shims-css' href='https://lexariabioscience.com/wp-content/plugins/easy-social-icons/css/font-awesome/css/v4-shims.min.css?ver=5.7.2' media='all' /> <link rel='stylesheet' id='cnss_css-css' href='https://lexariabioscience.com/wp-content/plugins/easy-social-icons/css/cnss.css?ver=1.0' media='all' /> <style id='wp-emoji-styles-inline-css'> img.wp-smiley, img.emoji { display: inline !important; border: none !important; box-shadow: none !important; height: 1em !important; width: 1em !important; margin: 0 0.07em !important; vertical-align: -0.1em !important; background: none !important; padding: 0 !important; } </style> <link rel='stylesheet' id='wp-block-library-css' href='https://lexariabioscience.com/wp-includes/css/dist/block-library/style.min.css?ver=6.7.1' media='all' /> <style id='classic-theme-styles-inline-css'> /*! This file is auto-generated */ .wp-block-button__link{color:#fff;background-color:#32373c;border-radius:9999px;box-shadow:none;text-decoration:none;padding:calc(.667em + 2px) calc(1.333em + 2px);font-size:1.125em}.wp-block-file__button{background:#32373c;color:#fff;text-decoration:none} </style> <style id='global-styles-inline-css'> :root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}:where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;}:where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;} :where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;} :where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;} :root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;} </style> <link rel='stylesheet' id='contact-form-7-css' href='https://lexariabioscience.com/wp-content/plugins/contact-form-7/includes/css/styles.css?ver=6.0' media='all' /> <link rel='stylesheet' id='font-awesome-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/font-awesome/css/font-awesome.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='themify-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/themify-icons/themify-icons.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='sgicon-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/stroke-gap-icons/style.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='vc_linecons-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/css/lib/vc-linecons/vc_linecons_icons.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='ts_labtechco_business_icon-css' href='https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/icon-picker/icon-libraries/ts-lab-icons/font/flaticon.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='ts-cs-google-fonts-css' href='//fonts.googleapis.com/css?family=Poppins%3A300%2C400%2C500%2C600%2C700%7CArimo%3A400%7CVollkorn%3A700%7CRoboto+Condensed%3A300%2C300italic%2C400%2Citalic%2C700%2C700italic%7CRoboto%3A500&ver=1.0.0' media='all' /> <link rel='stylesheet' id='ts-base-icons-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/ts-labtechco-icons/css/ts-labtechco-icons.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='perfect-scrollbar-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/perfect-scrollbar/perfect-scrollbar.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='chrisbracco-tooltip-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/chrisbracco-tooltip/chrisbracco-tooltip.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='multi-columns-row-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/multi-columns-row.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='ts-select2-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/select2/select2.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='flexslider-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/node_modules/flexslider/flexslider.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='slick-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/slick/slick.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='slick-theme-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/libraries/slick/slick-theme.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='prettyphoto-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/prettyphoto/css/prettyPhoto.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='bootstrap-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/bootstrap.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='bootstrap-theme-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/bootstrap-theme.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='labtechco-core-style-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/core.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='js_composer_front-css' href='https://lexariabioscience.com/wp-content/plugins/js_composer/assets/css/js_composer.min.css?ver=7.7.2' media='all' /> <link rel='stylesheet' id='labtechco-master-style-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/master.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='labtechco-responsive-style-css' href='https://lexariabioscience.com/wp-content/themes/labtechco/css/responsive.min.css?ver=6.7.1' media='all' /> <link rel='stylesheet' id='tste-labtechco-theme-style-css' href='https://lexariabioscience.com/wp-admin/admin-ajax.php?action=themestek_theme_css&ver=6.7.1' media='all' /> <script src="https://lexariabioscience.com/wp-includes/js/jquery/jquery.min.js?ver=3.7.1" id="jquery-core-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/jquery/jquery-migrate.min.js?ver=3.4.1" id="jquery-migrate-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/easy-social-icons/js/cnss.js?ver=1.0" id="cnss_js-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/b2i-investor-tools/js/wb_script.js?ver=1.0.7.8" id="whistleblower-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/themestek-labtechco-extras/js/jquery-resize.min.js?ver=6.7.1" id="jquery-resize-js"></script>   <script src="https://www.googletagmanager.com/gtag/js?id=GT-NSVFNVV" id="google_gtagjs-js" async></script> <script id="google_gtagjs-js-after"> /* <![CDATA[ */ window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);} gtag("set","linker",{"domains":["lexariabioscience.com"]}); gtag("js", new Date()); gtag("set", "developer_id.dZTNiMT", true); gtag("config", "GT-NSVFNVV"); /* ]]> */ </script>  <script></script><link rel="https://api.w.org/" href="https://lexariabioscience.com/wp-json/" /><link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://lexariabioscience.com/xmlrpc.php?rsd" /> <meta name="generator" content="WordPress 6.7.1" />  <style> .investor-menu.sticky-nav {position: fixed; left: 0; right: 0; margin-left: auto; margin-right: auto; background-color: transparent !important; width: 100%; z-index: 999; top: 60px;} .investor-menu.sticky-nav #menu-investors {background-color: #3A5DAE !important;} .investor-menu.sticky-nav .container {padding-left: 0; padding-right: 0;}</style>   <style> @media (max-width:844px) { div.investor-menu ul.menu li ul.sub-menu {display: block !important;} ul.sub-menu li {min-width: 100% !important; display: block !important; padding: 5px 0px;} ul.sub-menu {background: transparent !important; padding-left: 30px !important; margin-top: 5px !important;} .investor-menu li a {padding: 0 !important;} .investor-menu li {padding: 5px 0px;} .team-layout3.dir-item-wrap {min-width: 100%;} .team-layout3 .modal-window {min-width: 100%;} .news-right-btn {text-align: left !important;} .b2iHeadLinesHeadlineCell.b2iPlugInHeadLinesHeadlineCell {padding-bottom: 0 !important;} .full-row-grey .vc_row.container {max-width: 90%;} .latest-annual-section {text-align: center;} .latest-annual-section .SECLayout22PDF-formLinks {text-align: center !important;} .email-alerts-section h3 {text-align: center;} .company-overview-section h3 {line-height: 1.2em;} .company-overview-section .btn {min-width: 100%; margin-bottom: 5px;} }</style>   <style> #LibStoryDiv a {text-decoration: underline;} /* Contact */ @media (min-width:844px) { #b2iContact .b2iFormLabel {min-width: 100%; clear: both;} #b2iContact input, #b2iContact select, #b2iContact textarea {min-width: 100%; min-height: 45px;} #b2iContact #ContactEmail, #b2iContact #ContactCompany, #b2iContact #ContactMessage {min-width: 98% !important;} #b2iContact #b2iContactFirstNameRow, #b2iContact #b2iContactLastNameRow, #b2iContact #b2iContactRoleRow, #b2iContact #b2iContactPhoneRow {width: 48%; clear: none; display: inline-block;} #b2iContact #b2iContactFirstNameRow, #b2iContact #b2iContactRoleRow {margin-right: 1.5% !important;} #b2iContact #b2iContactSubmit {min-width: 200px; margin-top: 20px; margin-bottom: 20px;} #b2iContact .b2iFormLabel {font-weight:bold; margin-bottom: 5px; margin-top: 10px;} } @media (max-width:844px) { #b2iContact input, #b2iContact select, #b2iContact textarea {min-width: 100%; min-height: 45px;} #b2iContact #ContactEmail, #b2iContact #ContactCompany, #b2iContact #ContactMessage {min-width: 100% !important;} #b2iContact #b2iContactSubmit {margin-top: 20px; margin-bottom: 20px;} } #b2iContactSubmit {border: 1px solid #000; background: transparent; color: #000; font-size: 18px; cursor: pointer;} /* Email signup */ @media (min-width:844px) { #b2iEmailSignUp {width: 100%;} .b2iEmailDiv, .b2iFirstNameDiv, .b2iLastNameDiv, .b2iCompanyDiv {display: inline-block; width: 49%;} .b2iEmailInput {min-width: 95%;} }</style>   <style> .single .ts-titlebar-main-inner .entry-title {font-size: 30px; line-height: 1.3em;} .ir-contact-3-col {font-size: 16px !important;} @media (min-width:844px) { #LibStoryContainer {margin-top: 50px;} .investor-menu a {padding: 18px 8px !important; } .sub-menu {background: #f5f5f5 !important; box-shadow: 0 6px 12px rgba(0,0,0,.175);} .sub-menu a {color: #031b4e !important;} .sub-menu li {min-width: 100%; border-bottom: 1px solid #ddd;} .sub-menu .current-menu-item {background: #FFF !important;} .view-all-button {background: ##EBEFF7 !important; text-align: center; margin-top: -80px; padding: 0 0 50px 0px!important;} .view-all-button .vc_row.container .btn {margin-bottom: -30px !important;} } @media (max-width: 844px) { .view-all-button {background: ##EBEFF7 !important; text-align: center; margin-top: -120px; padding: 0 0 50px 0px!important;} .view-all-button .vc_row.container .btn {margin-bottom: -30px !important;} .page-id-8559 #DocItem76967, .page-id-8703 #DocItem76967 {min-width: 100% !important;} .DocItemImage {padding: 0 !important;} #DocItemTitle76967, #DocItemTitle76968 {text-align: center;} } #b2iLibNav {margin-top: 50px;} #b2iLibNav a {text-decoration: underline;} /* Tabs */ .vc_tta-tabs-list {border-bottom: 2px solid #3A5DAE !important;} .vc_tta-tabs-list .vc_tta-tab {color: #031b4e; border-left:2px solid #3A5DAE; border-top: 2px solid #3A5DAE; border-right: 2px solid #3A5DAE;} .vc_tta-tabs-list .vc_tta-tab.vc_active span {color: #FFF;} .vc_tta-tabs-list .vc_tta-tab a {border-radius: 0 !important;} .vc_tta-tabs-list .vc_tta-tab.vc_active, .vc_tta-tabs-list .vc_tta-tab.vc_active a {background: #3A5DAE !important;} #DocItem76968 img {width: 100%;} .DocItemImage {width: 100% !important; max-width: 100% !important;} .DocItem8 {padding: 0 !important; margin: 0 !important; max-width: 100% !important; width: 100% !important;} #DocItemTitle76968 { background: #3A5DAE; padding: 15px 0px; } #DocItemTitle76968 a { color: #FFF; } .page-id-8559 #DocItem76967, .page-id-8703 #DocItem76967 {min-width: 350px;} #DocItem76967 img {width: 100%;} #DocItem76967 {min-width: 100%; padding: 0; margin: 0;} #DocItemTitle76967 {background: #3A5DAE; padding: 15px 0px;} #DocItemTitle76967 a {color: #FFF;} .smaller-h3 h3 {font-size: 28px !important; } #press-releases .b2iLibToolsContainer select, #press-releases .b2iLibToolsContainer input {width: auto;} #press-releases #B2iLibSearchButton {margin-left: 5px;} .modal-dialog .dir-item-name, .modal-dialog .dir-item-title-text {line-height: 1.3em;} .amChartsPeriodSelectorButtonDiv {text-align: center;} .amChartsPeriodSelectorButtonDiv input[type="button"] {padding: 5px 10px; margin: 0 3px;} .team-layout3.dir-item-wrap {width: 23%;} .dir-item-photo-container img {min-width: 100%;} .dir-item-wrap_name-container, .team-layout3 .modal-content__header {background: #3A5DAE !important;} .dir-item-name {font-size: 15px;} .modal-content .dir-item-photo img {padding: 10px 10px 20px 10px;} .modal-content .dir-item-bio {font-size: 17px;} .modal-dialog, .modal-content {box-shadow: none !important;} .btn.ShowCaseLinkImage {color: #FFF; font-size: 16px; padding: 15px 35px; border: none;} #b2iSecForm select {width: auto;} #b2iSection23038 {padding-left: 0 !important; padding-right: 0 !important;} #b2iQuoteID10 .b2iClientQuote .b2iClientQuoteLabel {color: #333 !important;} .b2iPrimaryButton.b2iButton.b2iSecSearch.xxsmall {max-height: 30px; margin-left: 10px;} #b2iHistoricQuoteForm input {width: auto;} #b2iHistoricQuoteForm {padding-bottom: 30px;} .b2iSECtopSelectCell2 .select2 {width: auto !important; min-width: 250px;} .b2iSECtopSelect, .b2iSECtopSelecttd, .b2iSECtopSelect tr, .b2iSECtopTitleTable, .b2iSECtopTitleTable td, .b2iSECtopTitleTable tr, .b2iSECtopTitleTable th {border: none !important;} #b2iSecTop {margin-top: 20px;} .FilterLabel {margin-right: 5px; margin-left: 20px;} .b2iHeader.active, .b2iHeader:hover {background-color: #3A5DAE !important; color: #FFF; font-weight: 600;} .ir-content .document-report span, .ir-content .document-report {font-size: 19px;} .ir-content .document-report {padding-top: 20px;} .SECLayout16.SECItembutton-link a {background: #3A5DAE !important; font-size: 16px !important; font-weight: 600; padding: 15px 35px !important; box-shadow: none !important; } .b2iFinancialsHeader {line-height: 1.4em; margin-bottom: 20px;} .B2iFinancialsContainer, .B2iFinancialsContainer div, .B2iFinancialsContainer a {color: #333 !important;} .docDetails-col .DocItemTitle {margin-bottom: 5px;} #b2iEmailSignUp label {margin-left: 5px;} #b2iEmailSignUp input {border-radius: 0;} #b2iEmailList .b2iEmailFieldset {padding: 5px;} .ir-content .a-input-text, .ir-content .a-input-select, .ir-content .b2iFormRow input:not(.b2iEmailAlertCheckbox), .ir-content .b2iTextbox:not(.b2iEmailAlertCheckbox), .ir-content .InputDate, .ir-content #b2iSearchbox, .ir-content .b2iSelect {border-color: #3A5DAE; border-radius:0;} .ir-content {font-size: 19px;} .b2iPlugInHeadlinesDate {margin-top: 20px; margin-bottom: 2px !important;} .b2iLibToolsContainer .select2-selection__rendered {padding-left: 15px !important;} .ir-content .main-holder .site #content table.cart td.actions .input-text, .ir-content textarea, input[type="text"], .ir-content input[type="password"], .ir-content input[type="datetime"], .ir-content input[type="datetime-local"], .ir-content input[type="date"], .ir-content input[type="month"], .ir-content input[type="time"], .ir-content input[type="week"], .ir-content input[type="number"], .ir-content input[type="email"], .ir-content input[type="url"], .ir-content input[type="search"], .ir-content input[type="tel"], .ir-content input[type="color"], .ir-content .uneditable-input, .ir-content select {border: 1px solid #3A5DAE !important;} #b2iLibSearch input {margin-bottom: 10px; margin-top: 10px;} .ir-content button, .ir-content input[type="submit"], .ir-content input[type="button"], .ir-content input[type="reset"] {background-color: #3A5DAE;} .ir-content h3 {font-weight: 600; color: #031b4e; font-size: 36px; letter-spacing: -0.01em; margin-bottom: 20px; margin-top: 40px;} .ir-content, .ir-content a {color: #031b4e;} .current-menu-ancestor {background-color: rgba(0,0,0,0.3);} .inline-btns .btn {display: inline-block; margin-right: 4px;} .inline-btns br {display: none;} .page-id-8559 .ts-titlebar-main h1 {position: relative; z-index: 3;} .page-id-8559 .ts-titlebar-main .breadcrumb-wrapper {z-index: 2; position: relative;} .page-id-8559 .ts-titlebar-main:before {content: ''; position: absolute; z-index: 1; width: 100%; top: 0; left: 0; bottom: 0; background: #1B3C92; opacity: .5;} .stock-quote-section {background: #018A17; min-width: 100%; text-align: left; padding: 30px 0px 0px 0px;} .stock-quote-section .container {padding-left: 0 !important; padding-right: 0 !important;} .stock-quote-section .b2iQuote91data-title {color: #FFF; font-size:12px; } .stock-quote-section .b2iQuote91data, .stock-quote-section .data, .stock-quote-section .ChangeStyle {color: #FFF; font-size: 20px; font-weight: 700;} .ir-contacts-section {padding: 80px 0px 0px 0px !important;} .ir-contacts-section .ts-custom-heading {text-align: left;} .ir-contacts-data h3 {font-weight: 700; font-size: 20px; margin-top: 0; margin-bottom: 0; color: #031B4E;} .ir-contacts-data h4 {margin-top: 10px; color: #031B4E;} .ir-contacts-data {font-size: 18px; color: #212529; line-height: 1.3em;} .company-overview-section {padding: 80px 0px !important;} .company-overview-section h3 {font-weight: 600; font-size: 40px; letter-spacing: -0.02em; margin-bottom: 30px; margin-top: 0;} .company-overview-section p {color: #212529;} .company-overview-section .btn {margin-right: 5px; font-size: 15px;} .email-alerts-section h3 {color: #FFF; font-weight: 700; font-size: 40px; margin-top: 0;} .email-alerts-section {color: #FFF; padding: 60px 0px 20px 0px; background-size: cover; } .email-alerts-section p {font-size: 19px; letter-spacing: -0.02em; text-align: center;} .email-alerts-section .btn {color: #FFF; border-color: #FFF;} .email-signup-btn-col {text-align: right;} .latest-financial-results-section {padding: 80px 0px 40px 0px; background: #FFF!important;} .latest-1 .ts-cta3-content-wrapper {min-width: 100%;} .latest-1 .ts-custom-heading {text-align: left;} .latest-1 .flex.flex-third.filing-type {display: block !important; min-width: 100%; text-align: left;} .latest-1 .result-line {text-align: left; padding: 15px 0px !important;} .latest-1 a {color: #3A5DAE !important;} .latest-1 .filing-name {color: #031B4E; margin-top: 30px;} .latest-1 .qedate {color: #031B4E; margin-bottom: 10px;} .latest-1 .qedate span {display: inline-block; font-weight: 500; font-size: 12px;} .latest-1 .EndedSpan2 {margin-left: 5px;} .dots-img img {position: relative; z-index: 9;} .dots-img:after {content: ""; position: absolute; top: -54px; right: -40px; height: 136px; width: 132px; background: url(https://d1io3yog0oux5.cloudfront.net/_860e50159b1afe5949e7e2039c834240/lexariabioscience/files/theme/images/dots.svg) no-repeat center; background-size: 100%;} .dots-img-2 img {position: relative; z-index: 9;} .dots-img-2:after {content: ""; content: ""; position: absolute; bottom: -54px; left: -40px; height: 136px; width: 132px; background: url(https://d1io3yog0oux5.cloudfront.net/_860e50159b1afe5949e7e2039c834240/lexariabioscience/files/theme/images/dots.svg) no-repeat center; background-size: 100%;} .latest-annual-section .container {border-top: solid 1px #ddd; padding-top: 40px !important;} .latest-annual-section {background: #FFF !important; padding-bottom: 50px;} .latest-annual-section h3 {margin-top: 0; font-weight: 700;} .latest-annual-section h4 {margin-top: 10px;} .latest-annual-section h3, .latest-annual-section h4 {color: #031B4E !important;} .SECLayout22PDFItem-link.PDF-link a {color: #3A5DAE !important;} .SECLayout22PDF-formLinks {text-align: right;} .SECLayout22PDFItem-link.PDF-link {background: rgba(0, 0, 0, 0); display: inline-block; font-size: 16px; letter-spacing: normal; font-weight: 600; font-family: "Poppins", sans-serif; line-height: 1; margin-bottom: 5px; background: #FFF !important;border-radius: 0 !important; text-align: center; text-transform: none; white-space: normal; -moz-transition: background-color 0.2s ease, border-color 0.2s ease; -o-transition: background-color 0.2s ease, border-color 0.2s ease; -webkit-transition: background-color 0.2s ease, border-color 0.2s ease; transition: background-color 0.2s ease, border-color 0.2s ease; border: 2px solid #3A5DAE; color: #3A5DAE !important; margin: 0; padding: 15px 35px !important; border-radius: 0; text-decoration: none;} .news-right-btn {text-align: right;} .btn:hover {color: #FFF; background: #3A5DAE;} .btn {background: rgba(0, 0, 0, 0); display: inline-block; font-size: 16px; letter-spacing: normal; font-weight: 600; font-family: "Poppins", sans-serif; line-height: 1; margin-bottom: 5px; text-align: center; text-transform: none; white-space: normal; -moz-transition: background-color 0.2s ease, border-color 0.2s ease; -o-transition: background-color 0.2s ease, border-color 0.2s ease; -webkit-transition: background-color 0.2s ease, border-color 0.2s ease; transition: background-color 0.2s ease, border-color 0.2s ease; border: 2px solid #3A5DAE; color: #3A5DAE; margin: 0; padding: 15px 35px; border-radius: 0; text-decoration: none;} #b2iPlugInHeadLine {padding-left: 0;} #b2iPlugInHeadLine li {list-style: none;} .b2iPlugInHeadlinesDate {margin-bottom: 10px;} .news-2 .b2iLibraryHeadlineLink {font-size: 18px !important; font-weight:400; text-decoration: underline;} .news-2 .b2iPlugInHeadlinesItem {margin-bottom:25px;} .b2iHeadLinesDateCell, .b2iPlugInHeadlinesDate {font-size:12px; text-transform: none; font-weight: 400; color: #031B4E;} .news-2 #b2iLibNav, .news-1 #b2iLibNav {display: none;} .full-row-grey {background: #EBEFF7; padding: 60px 0px; } .full-row-grey .vc_row.container { padding: 30px 30px 30px 30px !important; background: #FFF; } .full-row-grey h3 {font-weight: 700; letter-spacing: -0.01em; font-size: 20px;} .ts-titlebar-main h1 {font-family: 'Poppins' !important; text-transform: none !important; letter-spacing: -0.02em !important;} div.investor-menu li.current-menu-item {background-color: rgba(0,0,0,0.3);} .b2iPressContainer table, .b2iPressContainer tr, .b2iPressContainer td {border: none;} .b2iHeadLinesHeadlineCell a {font-weight: 400; text-decoration: underline; font-size: 26px; line-height: 1.3em;} div.investor-menu {background-color: #3A5DAE !important;} div.investor-menu a {font-size: 13px; font-weight: 700; line-height: 1.4em; letter-spacing: 0;} div.investor-menu li {display: inline-block; float: none; position: relative; text-align: left;} /* Basic styles for the menu container */ div.investor-menu { background-color: #333; position: relative; } /* Style for the main menu items */ div.investor-menu ul.menu { list-style-type: none; margin: 0; padding: 0; display: flex; flex-direction: row; /* Align items horizontally */ } /* Style for individual menu items */ div.investor-menu ul.menu > li { position: relative; } /* Style for links */ div.investor-menu ul.menu > li > a { display: block; color: white; text-align: center; padding: 14px 16px; text-decoration: none; } /* Change color on hover */ div.investor-menu ul.menu > li > a:hover { background-color: #111; } /* Style for the dropdown */ div.investor-menu ul.menu li ul.sub-menu { display: none; position: absolute; background-color: #333; min-width: 160px; z-index: 999; list-style-type: none; margin: 0; padding: 0; } /* Style for dropdown links */ div.investor-menu ul.menu li ul.sub-menu li a { padding: 12px 16px; text-decoration: none; display: block; text-align: left; color: white; } /* Show the dropdown on hover */ div.investor-menu ul.menu li:hover ul.sub-menu { display: block; } /* Hamburger menu styles */ div.investor-menu .hamburger { display: none; font-size: 30px; color: white; padding: 14px 16px; cursor: pointer; } /* Media query for screens 1000px or smaller */ @media screen and (max-width: 1000px) { /* Stack the menu items vertically */ div.investor-menu ul.menu { flex-direction: column; display: none; /* Hide menu by default */ width: 100%; } /* Show the hamburger icon */ div.investor-menu .hamburger { display: block; } /* Show menu when active */ div.investor-menu ul.menu.active { display: flex; } /* Style for links in vertical mode */ div.investor-menu ul.menu > li > a { text-align: left; padding: 12px 16px; } /* Dropdowns in vertical mode */ div.investor-menu ul.menu li ul.sub-menu { position: relative; } } </style>  <style> ul.cnss-social-icon li.cn-fa-icon a{background-color:#3a5dae!important;} ul.cnss-social-icon li.cn-fa-icon a:hover{background-color:#264899!important;color:#ffffff!important;} </style><meta name="generator" content="Site Kit by Google 1.140.0" /><meta name="generator" content="Powered by WPBakery Page Builder - drag and drop page builder for WordPress."/>  <script> /* <![CDATA[ */ ( function( w, d, s, l, i ) { w[l] = w[l] || []; w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} ); var f = d.getElementsByTagName( s )[0], j = d.createElement( s ), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore( j, f ); } )( window, document, 'script', 'dataLayer', 'GTM-KNPGWSZ' ); /* ]]> */ </script>  <meta name="generator" content="Powered by Slider Revolution 6.5.15 - responsive, Mobile-Friendly Slider Plugin for WordPress with comfortable drag and drop interface." /> <link rel="icon" href="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-32x32.png" sizes="32x32" /> <link rel="icon" href="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-192x192.png" sizes="192x192" /> <link rel="apple-touch-icon" href="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-180x180.png" /> <meta name="msapplication-TileImage" content="https://lexariabioscience.com/wp-content/uploads/2022/06/cropped-Lexaria_Bioscience_Logo_Square_SocialMedia_A-270x270.png" /> <script>function setREVStartSize(e){ //window.requestAnimationFrame(function() { window.RSIW = window.RSIW===undefined ? window.innerWidth : window.RSIW; window.RSIH = window.RSIH===undefined ? window.innerHeight : window.RSIH; try { var pw = document.getElementById(e.c).parentNode.offsetWidth, newh; pw = pw===0 || isNaN(pw) ? window.RSIW : pw; e.tabw = e.tabw===undefined ? 0 : parseInt(e.tabw); e.thumbw = e.thumbw===undefined ? 0 : parseInt(e.thumbw); e.tabh = e.tabh===undefined ? 0 : parseInt(e.tabh); e.thumbh = e.thumbh===undefined ? 0 : parseInt(e.thumbh); e.tabhide = e.tabhide===undefined ? 0 : parseInt(e.tabhide); e.thumbhide = e.thumbhide===undefined ? 0 : parseInt(e.thumbhide); e.mh = e.mh===undefined || e.mh=="" || e.mh==="auto" ? 0 : parseInt(e.mh,0); if(e.layout==="fullscreen" || e.l==="fullscreen") newh = Math.max(e.mh,window.RSIH); else{ e.gw = Array.isArray(e.gw) ? e.gw : [e.gw]; for (var i in e.rl) if (e.gw[i]===undefined || e.gw[i]===0) e.gw[i] = e.gw[i-1]; e.gh = e.el===undefined || e.el==="" || (Array.isArray(e.el) && e.el.length==0)? e.gh : e.el; e.gh = Array.isArray(e.gh) ? e.gh : [e.gh]; for (var i in e.rl) if (e.gh[i]===undefined || e.gh[i]===0) e.gh[i] = e.gh[i-1]; var nl = new Array(e.rl.length), ix = 0, sl; e.tabw = e.tabhide>=pw ? 0 : e.tabw; e.thumbw = e.thumbhide>=pw ? 0 : e.thumbw; e.tabh = e.tabhide>=pw ? 0 : e.tabh; e.thumbh = e.thumbhide>=pw ? 0 : e.thumbh; for (var i in e.rl) nl[i] = e.rl[i]<window.RSIW ? 0 : e.rl[i]; sl = nl[0]; for (var i in nl) if (sl>nl[i] && nl[i]>0) { sl = nl[i]; ix=i;} var m = pw>(e.gw[ix]+e.tabw+e.thumbw) ? 1 : (pw-(e.tabw+e.thumbw)) / (e.gw[ix]); newh = (e.gh[ix] * m) + (e.tabh + e.thumbh); } var el = document.getElementById(e.c); if (el!==null && el) el.style.height = newh+"px"; el = document.getElementById(e.c+"_wrapper"); if (el!==null && el) { el.style.height = newh+"px"; el.style.display = "block"; } } catch(e){ console.log("Failure at Presize of Slider:" + e) } //}); };</script> <noscript><style> .wpb_animate_when_almost_visible { opacity: 1; }</style></noscript></head> <body class="archive date ts-headerstyle-infostack themestek-wide themestek-sidebar-true themestek-sidebar-right wpb-js-composer js-comp-ver-7.7.2 vc_responsive">  <noscript> <iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KNPGWSZ" height="0" width="0" style="display:none;visibility:hidden"></iframe> </noscript>  <div id="ts-home"></div> <div class="main-holder"> <div id="page" class="hfeed site"> <header id="masthead" class=" ts-header-style-infostack themestek-main-menu-total-5"> <div class="ts-header-block ts-mmenu-active-color-custom ts-dmenu-active-color-skin ts-dmenu-sep-grey"> <div id="site-header" class="site-header ts-bgcolor-transparent ts-sticky-bgcolor-white ts-mmmenu-override-yes ts-above-content-yes"> <div class="site-header-main ts-table"> <div class="ts-header-top-wrapper container"> <div class="site-branding"> <div class="headerlogo themestek-logotype-image ts-stickylogo-no"><span class="site-title"><span class="logo-link-text">Lexaria Bioscience - </span><a class="home-link" href="https://lexariabioscience.com/" title="Lexaria Bioscience" rel="home"><span class="ts-sc-logo ts-sc-logo-type-image"><img class="themestek-logo-img standardlogo" alt="Lexaria Bioscience" src=" http://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png"></span></a></span><h2 class="site-description"></h2></div> </div> <div class="ts-infostack-right-content"> <div class="info-widget"> <div class="info-widget-inner"> </div> </div> <div class="info-widget"> <div class="info-widget-inner"> </div> </div> <div class="info-widget"> <div class="info-widget-inner"> NASDAQ:LEXX; NASDAQ WARRANT:LEXXW </div> </div> </div> </div> <div id="ts-stickable-header-w" class="ts-stickable-header-w ts-bgcolor-transparent" style="height:60px"> <div id="site-header-menu" class="site-header-menu container"> <div class="site-header-menu-inner ts-stickable-header ts-header-menu-bg-color-skincolor ts-bgcolor-skincolor ts-sticky-bgcolor-darkgrey"> <div class="site-header-menu-middle ts-header-menu-bg-color-skincolor ts-bgcolor-skincolor ts-sticky-bgcolor-darkgrey"> <div class="container "> <div> <nav id="site-navigation" class="main-navigation" aria-label="Primary Menu" data-sticky-height="90"> <button id="menu-toggle" class="menu-toggle"> <span class="ts-hide">Toggle menu</span><i class="ts-labtechco-icon-bars"></i> </button> <div class="nav-menu"><ul id="menu-main-menu" class="nav-menu"><li id="menu-item-7921" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-home menu-item-7921"><a href="https://lexariabioscience.com/">Home</a></li> <li id="menu-item-7917" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-7917"><a href="https://lexariabioscience.com/about-lexaria/">About</a> <ul class="sub-menu"> <li id="menu-item-7918" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7918"><a href="https://lexariabioscience.com/about-lexaria/#management">Management</a></li> <li id="menu-item-7948" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7948"><a href="https://lexariabioscience.com/about-lexaria/#board-of-directors">Board of Directors</a></li> <li id="menu-item-7949" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7949"><a href="https://lexariabioscience.com/about-lexaria/#advisors-and-consultants">Advisors & Consultants</a></li> </ul> </li> <li id="menu-item-7981" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-has-children menu-item-7981"><a href="https://lexariabioscience.com/technology/">Technology</a> <ul class="sub-menu"> <li id="menu-item-7987" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7987"><a href="https://lexariabioscience.com/technology/">Overview</a></li> <li id="menu-item-7989" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-7989"><a href="https://lexariabioscience.com/technology/#commercial-applications">Commercial Applications</a></li> <li id="menu-item-7982" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-7982"><a href="https://lexariabioscience.com/research/">Research</a></li> <li id="menu-item-8016" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-8016"><a href="https://lexariabioscience.com/patent-portfolio/">Patent Portfolio</a></li> </ul> </li> <li id="menu-item-8020" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-8020"><a href="https://lexariabioscience.com/licensing-opportunities/">Licensing Opportunities</a></li> <li id="menu-item-8025" class="menu-item menu-item-type-custom menu-item-object-custom menu-item-8025"><a href="https://lexariabioscience.com/investors/">Investors</a></li> </ul></div> </nav> </div> <div class="ts-phone"> <div class="ts-header-text-area ts-header-button-w"> <div class="ts-vc_btn3-container ts-vc_btn3-inline"><a class="ts-vc_general ts-vc_btn3 ts-vc_btn3-size-md ts-vc_btn3-shape-square ts-vc_btn3-style-flat ts-vc_btn3-weight-yes ts-vc_btn3-color-skincolor" href="https://lexariabioscience.com/contact/" title="">Contact</a></div></div> </div> </div> </div> </div> </div> </div> </div> </div> <div class="ts-titlebar-wrapper ts-bg ts-bgcolor-transparent ts-titlebar-align-left ts-textcolor-white ts-bgimage-yes"> <div class="ts-titlebar-wrapper-bg-layer ts-bg-layer"></div> <div class="ts-titlebar entry-header"> <div class="ts-titlebar-inner-wrapper"> <div class="ts-titlebar-main"> <div class="container"> <div class="ts-titlebar-main-inner"> <div class="entry-title-wrapper"><div class="container"><h1 class="entry-title"> Yearly Archives: <span>2023</span></h1></div></div><div class="breadcrumb-wrapper"><div class="container"><div class="breadcrumb-wrapper-inner"><span><a title="Go to Lexaria Bioscience." href="https://lexariabioscience.com" class="home"><i class="fa fa-home"></i><span class="hide">Lexaria Bioscience</span></a></span> <span class="ts-bread-sep">   →  </span><span><a title="Go to Blog Large Image." href="https://lexariabioscience.com/blog-large-image/" class="post-root post post-post"><span>Blog Large Image</span></a></span><span class="ts-bread-sep">   →  </span><span><span class="archive date-year current-item">2023</span></span></div></div></div> </div> </div> </div> </div> </div> </div> </div> </header> <div id="content-wrapper" class="site-content-wrapper"> <div id="content" class="site-content container"> <div id="content-inner" class="site-content-inner row multi-columns-row"> <div id="primary" class="content-area col-md-9 col-lg-9 col-xs-12"> <main id="main" class="site-main"> <article id="post-9046" class="ts-no-featured-content themestek-box-blog-classic post-9046 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">07</div> <div class="ts-blog-classic-dbox-month">Dec</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2023/12/07/lexarias-investigational-new-drug-application-filing-update/">December 7, 2023</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2023/12/07/lexarias-investigational-new-drug-application-filing-update/">Lexaria’s Investigational New Drug Application Filing Update</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><strong>KELOWNA, BC / December 7, 2023 /</strong> Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that the Company's anticipated submission of an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its planned U.S. Phase 1b Hypertension Clinical Trial is expected to be filed within approximately 45 days.</p><p><a href="https://pr.report/XqajdC3r">As previously announced</a>, this filing was regrettably delayed while Lexaria awaited overdue documentation from one of its key raw material suppliers. Lexaria is pleased to announce that the supplier in question has updated much of this documentation with Lexaria and directly with the FDA, which will now enable Lexaria to complete final integration of this information into its IND application. The supplier has recently informed Lexaria that, within approximately 45 days, it expects to submit its two final pieces of outstanding information with the FDA, following which Lexaria will be able to proceed with filing our IND application.</p><p>Lexaria feels confident, given that from 2018 through 2022 it has previously conducted five human clinical trials studying DehydraTECH-CBD in an aggregate total of 134 people, without recording a single serious adverse event (the "Studies"), that it's proposed Phase 1b study plan will not expose test subjects to unreasonable risk. Lexaria looks forward to submitting this important IND filing and hopes that the review process proceeds smoothly toward effectiveness in the subsequent <a href="https://pr.report/haeifBLT">30 day period allotted by the FDA</a>.</p><p><strong>Background and Medical/Market Rationale</strong></p><p>The Studies, which were not conducted under FDA-registration but are integral to successful filing and review of Lexaria's planned IND submission, were carried out in an aggregate total of 134 healthy and hypertensive persons. The Studies evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens, and also produced zero serious adverse events; suggesting that DehydraTECH-CBD has the potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.</p><p>Lexaria is aware of only a handful of <a href="https://pr.report/Kk9erzGE">other published research studies</a>, mostly in young, healthy and normotensive volunteers, that have investigated whether a sustained decrease in resting blood pressure is possible following multiple weeks of oral CBD dosing; none of which have been successful in achieving this. DehydraTECH-CBD is currently unique in its evidenced superior power to reduce blood pressure over other oral CBD formulations.</p><p>Findings from Lexaria's latest study HYPER-H21-4 <a href="https://pr.report/u8RXQU0T">demonstrated a potentially novel mechanism of action</a> of DehydraTECH-CBD in reducing blood pressure which may be explained, at least in part, by its interaction with the human sympatho-chromaffin system via catestatin modulation as detailed in the <a href="https://pr.report/aND8kVW7">peer-reviewed and published</a> journal, "<i>Biomedicine and Pharmacotherapy</i>". This is significant because the FDA has previously communicated <a href="https://pr.report/DGgrCMOv">clear guidelines for sponsors</a> who seek to develop new anti-hypertensive drugs, specifically defining the need for medications that offer novel and complementary modes of action. Data gathered from study HYPER-H21-4 suggested that DehydraTECH-CBD had the potential to offer <a href="https://pr.report/7bP2DN4O">additive blood pressure reduction benefits</a> in addition to any degree of improvements that standard of care medications achieved for patients prior to DehydraTECH-CBD dosing.</p><p><strong>About Planned Clinical Trial HYPER-H23-1</strong></p><p>Clinical trial HYPER-H23-1 is entitled '<i>A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension'</i>. The primary objective of the trial will be to evaluate safety and tolerability in hypertensive patients, and secondary objectives will include efficacy evaluation in reducing blood pressure together with detailed pharmacokinetic testing.</p><p>All clinical, laboratory and analysis procedures for study HYPER-H23-1 are to be performed entirely by U.S.-based, third-party independent contract service providers.</p><p><strong>About Lexaria Bioscience Corp. & DehydraTECH</strong></p><p>DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, Lexaria has developed and investigated DehydraTECH with a variety of beneficial molecules in oral and topical formats. DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption and has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/kf8Bduqm">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#462f34062a233e27342f27242f2935252f232825236825292b"><span class="__cf_email__" data-cfemail="4a23380a262f322b38232b2823253929232f24292f64292527">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/814185/lexarias-investigational-new-drug-application-filing-update'>https://www.accesswire.com/814185/lexarias-investigational-new-drug-application-filing-update</a><br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2023/12/07/lexarias-investigational-new-drug-application-filing-update/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2023/12/07/lexarias-investigational-new-drug-application-filing-update/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9047" class="ts-no-featured-content themestek-box-blog-classic post-9047 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">28</div> <div class="ts-blog-classic-dbox-month">Nov</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2023/11/28/lexarias-technology-lowers-blood-glucose-more-effectively-than-rybelsus-branded-glp-1-drug-semaglutide-alone-in-human-pilot-study/">November 28, 2023</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2023/11/28/lexarias-technology-lowers-blood-glucose-more-effectively-than-rybelsus-branded-glp-1-drug-semaglutide-alone-in-human-pilot-study/">Lexaria’s Technology Lowers Blood Glucose More Effectively than Rybelsus®-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><i><strong>DehydraTECH<sup>TM</sup>-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus</strong></i><strong>®</strong><i><strong>:</strong></i></p><ul><li><i><strong>Sustained lower levels of blood glucose from baseline including nearly 10x lower after 24 hours;</strong></i></li><li><i><strong>Lower blood-glucose spike after eating; and</strong></i></li><li><i><strong>Successful first-ever DehydraTECH test with a "large molecule" drug.</strong></i></li></ul><p><strong>KELOWNA, BC / November 28, 2023</strong> <strong>/</strong> Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces additional positive interim results from a human pilot study (the "<strong>Study</strong>") evaluating DehydraTECH<sup>TM</sup> technology for the <i>oral</i> delivery of the glucagon-like peptide-1 ("<strong>GLP-1</strong>") drug semaglutide available commercially in the branded product Rybelsus®, further to its <a href="https://pr.report/Gh8p9u60">previously announced findings</a> from this work.</p><p>The Study was performed by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus tablet ("<strong>Control</strong>") to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements ("<strong>DehydraTECH GLP-1</strong>").</p><p><strong>Blood Glucose Levels</strong><br />It is accepted by the Food and Drug Administration ("<strong>FDA</strong>") that, "<a href="https://pr.report/8ujIkgPl"><i>one role of GLP-1</i></a><i> is to prompt the body to produce more insulin, which reduces blood glucose (sugar)</i>." Because blood glucose levels are a key consideration in control of diabetes and other health conditions, the Study measured blood glucose levels at each of the 19 sample time points.</p><p><strong>Blood Glucose Levels</strong></p><figure class="image image_resized" style="width:100%;text-align:center;margin:0.9em auto"><img src="https://www.accesswire.com/users/newswire/images/810542/image.jpg" width="100%" /></figure><div style="clear: both"> </div><div> </div><div> </div><div> </div><div> </div><div> </div><div> </div><div> </div><p>Rybelsus (blue) 7mg (n=3) DehydraTECH (orange) GLP-1 7mg (n=4)</p><p>The Control group evidenced reduced blood glucose levels by between 1.3% and 6.7% relative to the time zero baseline during the first 100 minutes of the Study. The DehydraTECH GLP-1 group evidenced reduced blood glucose levels by between 2.9% and 14.6% relative to baseline during those same initial 100 minutes. At all but the 20-minute and 240-minute sample time points, the DehydraTECH GLP-1 blood glucose levels were reduced more than evidenced by the Control group.</p><p>Notably, even as long as 24 hours after dose administration, the blood glucose levels were reduced in the DehydraTECH GLP-1 group by 6.3% relative to baseline while the blood glucose level evidenced in the Control group was only reduced by 0.67%, evidencing nearly a ten-fold improvement with the DehydraTECH GLP-1. (Only the first 10 hours of study results displayed in the graph above.)</p><p>Of particular note, blood glucose levels spiked by 22.7% in the Control group after the subjects were permitted to eat a standardized meal at the 240-minute mark and a standardized snack at the 360-minute mark. Although the DehydraTECH GLP-1 subjects consumed choices of similar meals and snacks at the same times, their blood glucose levels rose by only 5.3%. It is not presently known whether the higher sustained levels of blood semaglutide delivery by DehydraTECH GLP-1 enabled greater efficacy in achieving sustained blood glucose reduction, thereby helping to attenuate the postprandial spikes in blood glucose experienced in the Control group, although this may be a plausible explanation for the difference.</p><p>This Study is only meant to provide early-stage indicative information to Lexaria about the possibility of enhancing the pharmacokinetic ("PK") and pharmacodynamic performance of orally delivered GLP-1 drugs to assist in guiding the Lexaria team in additional investigations. There was minor variability in the diets of the subjects at the 240-minute meal and 360-minute snack intervals noted above during the concentrated 10-hour post dosing monitoring period which could account for some of the differences in the test data, although meal and snack selection allowance was from a set of standardized choices.</p><p><strong>Ongoing and Future Work</strong><br />This Study is not complete and additional results will be reported, likely in late December or early January following the cross-over Study visit as described below. Given the small sample size of this Study, it was not sufficiently powered for statistical significance analysis, which will be a key part of any expanded studies with DehydraTECH GLP-1 undertaken in the future.</p><p>Parallel to Lexaria's 2021 optimization program with DehydraTECH-processed cannabidiol ("CBD"), where the formulation utilized in the <a href="https://pr.report/5DLORpeB">animal study</a> DIAB-A22-1 <a href="https://pr.report/L8ib3DMy">demonstrated 364% higher</a> (p=0.0002) PK performance than Lexaria's original DehydraTECH-CBD formulations, we expect to create several different DehydraTECH GLP-1 formulations to explore delivery and performance optimization of semaglutide. As seen with our past DehydraTECH-CBD advancements, Lexaria will endeavor to similarly improve performance of future DehydraTECH-GLP-1 formulations.</p><p><strong>About the Study</strong><br />The Study was performed to provide an early-stage indication of whether DehydraTECH processing could improve <i>oral</i> drug delivery characteristics of the GLP-1 drug semaglutide sold as Rybelsus. A single semaglutide dose of 7 mg of the Rybelsus Control was compared to the matching dose of the DehydraTECH GLP-1, swallowed by each subject after an overnight fasting period together with a 50 mL glass of water. The DehydraTECH GLP-1 formulation used in this Study was compound formulated strictly for research purposes. Seven healthy subjects were dosed, four of whom received the DehydraTECH GLP-1, and three of whom received the Control. These seven subjects are expected to return to the Study site in December to be dosed a second time in the reverse order following the "cross-over" design of this Study to ensure that all seven subjects will have been treated with both the Control and DehydraTECH GLP-1 treatments over the course of the two visits.</p><p>Semaglutide is the first so-called "large molecule" ever evaluated with DehydraTECH processing. Lexaria has typically worked with drugs and bioactive substances that are considered "small molecules" with low molecular weights. Large molecules, on the other hand, generally have much larger molecular weights of 3000 daltons or greater, are often but not always <a href="https://pr.report/vEOGm8pB">biolocially derived</a> and are obviously more complex. At this time Lexaria does not know whether DehydraTECH may offer performance improvements to any significant quantity of large molecule drugs, but, if so, this could represent a <a href="https://pr.report/mENtJgv0">radically expanded suite of drugs</a> that may potentially be processed with DehydraTECH.</p><p><strong><u>About Lexaria's Diabetes Study Program.</u></strong><br />Lexaria began its DehydraTECH diabetes-related formal studies in 2022. On <a href="https://pr.report/R0J3qMtl">March 2, 2023</a> and <a href="https://pr.report/mTz0-ON8">June 16, 2023</a> Lexaria announced that in pre-clinical diabetes study <a href="https://pr.report/Sw8xLW1J">DIAB-A22-1</a> in obese diabetic-conditioned animals, DehydraTECH-CBD achieved each of the following:</p><ul><li>Lowered blood glucose levels by 19.9% (p<0.05)</li><li>Lowered overall body weight by 7% sustained over 8 weeks</li><li>Increased locomotor activity (p<0.05)</li><li>Lowered triglyceride levels by more than 25% (p<0.007)</li><li>Lowered blood urea nitrogen levels by 27.9% (p<0.001)</li></ul><p>On August 2, 2023 <a href="https://pr.report/isxv1to6">Lexaria announced its intention</a> to study weight loss and diabetes control in a human population using DehydraTECH-CBD.</p><p>DehydraTECH-CBD's ability to reduce blood sugar levels in animals is extremely encouraging and warrants additional investigation. According to the Center for Disease Control, <a href="https://www.cdc.gov/diabetes/managing/manage-blood-sugar.html#:~:text=It's%20important%20to%20keep%20your,improve%20your%20energy%20and%20mood.">managing your blood sugar levels</a> is important to avoid diabetes-related conditions such as vision loss, heart disease, and kidney disease. Limited research, mostly in animal studies, indicates that without DehydraTECH's noteworthy performance enhancements, <a href="https://diabetes.org/healthy-living/medication-treatments/cbd-diabetes#:~:text=There's%20a%20lot%20of%20hype,people%20with%20type%202%20diabetes.">generic CBD might be ineffective in controlling blood sugars</a>.</p><p><strong>About DehydraTECH</strong><br />DehydraTECH is a patented drug delivery formulation and processing platform technology Lexaria has developed and is investigating for a variety of beneficial molecules. DehydraTECH is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria has also developed DehydraTECH formulations for other applications demonstrating superior bio-absorption when administered intraorally and topically.</p><p><strong>About Lexaria Bioscience Corp.</strong><br />Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/CaqMQLHD">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong><br />This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong><br /><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#e9809ba9858c91889b80888b80869a8a808c878a8cc78a8684"><span class="__cf_email__" data-cfemail="f79e85b79b928f96859e96959e9884949e92999492d994989a">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE: </strong>Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/810542/lexarias-technology-lowers-blood-glucose-more-effectively-than-rybelsusr-branded-glp-1-drug-semaglutide-alone-in-human-pilot-study'>https://www.accesswire.com/810542/lexarias-technology-lowers-blood-glucose-more-effectively-than-rybelsusr-branded-glp-1-drug-semaglutide-alone-in-human-pilot-study</a><br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2023/11/28/lexarias-technology-lowers-blood-glucose-more-effectively-than-rybelsus-branded-glp-1-drug-semaglutide-alone-in-human-pilot-study/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2023/11/28/lexarias-technology-lowers-blood-glucose-more-effectively-than-rybelsus-branded-glp-1-drug-semaglutide-alone-in-human-pilot-study/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9081" class="ts-no-featured-content themestek-box-blog-classic post-9081 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">27</div> <div class="ts-blog-classic-dbox-month">Nov</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2023/11/27/lexarias-technology-improves-the-oral-performance-of-the-rybelsus-branded-glp-1-drug-semaglutide-in-human-pilot-study/">November 27, 2023</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2023/11/27/lexarias-technology-improves-the-oral-performance-of-the-rybelsus-branded-glp-1-drug-semaglutide-in-human-pilot-study/">Lexaria’s Technology Improves the Oral Performance of the Rybelsus®-Branded GLP-1 drug Semaglutide in Human Pilot Study</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><i><strong>DehydraTECH<sup>TM</sup>-powered semaglutide achieved these benefits in a human pilot study compared to Rybelsus</strong></i><strong>®</strong><i><strong>:</strong></i></p><ul><li><i><strong>Sustained higher levels of semaglutide in blood;</strong></i></li><li><i><strong>Faster achievement of peak drug delivery; and</strong></i></li><li><i><strong>Reduced side effects.</strong></i></li></ul><p><strong>KELOWNA, BC / November 27, 2023</strong> / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces positive interim results from a human pilot study (the "<strong>Study</strong>") currently underway evaluating DehydraTECH<sup>TM</sup> technology for the <i>oral</i> delivery of the glucagon-like peptide-1 ("<strong>GLP-1</strong>") drug semaglutide available commercially in the branded product Rybelsus®.</p><p>The Study is being performed by a prominent university research center comparing a single 7 mg semaglutide dose of a Rybelsus tablet ("<strong>Control</strong>") to a matching dose from Rybelsus that had been compound formulated in capsule form using DehydraTECH processing technology enhancements ("<strong>DehydraTECH GLP-1</strong>").</p><p><strong>Blood Levels of Semaglutide</strong></p><p>Blood was examined by a third-party laboratory using a validated bioassay 18 times over the first 10 hours of the Study, and once again 24 hours after the dose was administered. Subjects were supervised and monitored in the Study site over the entire 10-hour duration post dosing, and then allowed to depart, resume normal activities and return to the Study site the following day for performance of the 24-hour evaluation time point. The first post-baseline blood was sampled 20 minutes after oral administration and, at that point in time, the DehydraTECH GLP-1 blood semaglutide level was ~125% higher than that of the Control. At each of the 19 blood sample time points, the DehydraTECH GLP-1 blood semaglutide levels were higher than the Control levels. Furthermore, the DehydraTECH GLP-1 peak was achieved faster at 120 minutes (as compared to 160 minutes for the Control) and with a 16% higher blood semaglutide level than the Control. Of note, the blood semaglutide levels achieved with the Control were proportional to those achieved by <a href="https://pr.report/KCqpo5If">other researchers</a> in similar single dose cross-over Rybelsus development informing studies, further suggesting that the blood semaglutide level gains evidenced by the DehydraTECH GLP-1 formulation were notably distinct relative to the commercial product.</p><p style="text-align:center"><strong>Blood Levels of Semaglutide</strong></p><figure class="image image_resized" style="width:100%;text-align:center;margin:0.9em auto"><img src="https://www.accesswire.com/users/newswire/images/809947/image.jpg" width="100%" /></figure><div style="clear: both"> </div><div> </div><div> </div><div> </div><div> </div><div> </div><div> </div><p style="text-align:center">Rybelsus (blue) 7mg (n=3) DehydraTECH (orange) GLP-1 7mg (n=4)</p><p>Interestingly, even 24 hours after dose administration, the DehydraTECH GLP-1 blood semaglutide levels were still approximately 25% higher than the Control levels (Note - only the first 10 hours post dosing is shown in the graph above). Overall, the total semaglutide drug quantity based on the area under the curve or "AUC" delivered by the two interventions over the course of the 24 hour Study monitoring period was approximately 15% higher in the case of the DehydraTECH-GLP-1 versus that of the Control.</p><p><strong>Side Effects</strong></p><p>Two of the three Control subjects and zero of the four DehydraTECH GLP-1 subjects reported experiencing moderate nausea. All three Control subject reported experiencing mild nausea at both the 2-hour and 10-hour timepoints whereas only one DehydraTECH GLP-1 subject reported mild nausea and only at the single, 2-hour timepoint.</p><p><strong>Ongoing and Future Work</strong></p><p>This Study is only meant to provide early-stage indicative information to Lexaria about the possibility of enhancing the pharmacokinetic ("PK") and pharmacodynamic performance of orally delivered GLP-1 drugs to assist in guiding the Lexaria team in additional investigations.</p><p>This Study is not complete and additional results will be reported, likely in two tranches: Lexaria has also collected blood glucose data and expects to release those interim results imminently. Then, once the cross-over Study visit as described below has been conducted, final results from the Study should be available in late December or early January. Given the small sample size of this Study, it was not sufficiently powered for statistical significance analysis, which will be a key part of any expanded studies with DehydraTECH GLP-1 undertaken in the future.</p><p>Parallel to Lexaria's 2021 optimization program with DehydraTECH-processed cannabidiol ("CBD"), where the formulation utilized in the <a href="https://pr.report/lwRE-f09">animal study</a> DIAB-A22-1 <a href="https://pr.report/8Fqw2ly3">demonstrated 364% higher</a> (p=0.0002) PK performance than Lexaria's original DehydraTECH-CBD formulations, we expect to create several different DehydraTECH GLP-1 formulations to explore delivery and performance optimization of semaglutide. As seen with our past DehydraTECH-CBD advancements, Lexaria will endeavor to similarly improve performance of future DehydraTECH-GLP-1 formulations.</p><p>Lexaria has demonstrated in many previous R&D programs, including five human clinical studies, that DehydraTECH can greatly improve the PK performance of many orally administered drugs into the bloodstream. Like many of these agents, GLP-1 drugs also <a href="https://pr.report/65sjNVOQ">exhibit very poor oral bioavailability</a> (as little as 0.8%) without the use of absorption enhancement technology, such as Lexaria's DehydraTECH. As noted above, <a href="https://pr.report/2zBbtH4T">DIAB-A22-1 evidenced</a> DehydraTECH-CBD lowering body weight over a sustained dosing period by 7%, and also lowered blood sugar and triglyceride levels.</p><p>Design has already begun of a comprehensive animal PK and efficacy modelling study program to pursue these goals using different DehydraTECH compositions and different GLP-1 drug molecules. The Company cannot know in advance whether future formulations will perform better or worse than that which was used in the current Study. We are currently planning to begin the DehydraTECH-GLP-1 animal study during Q1, 2024.</p><p>Separately, Lexaria is also exploring the possibility of studying DehydraTECH-GLP-1 in a multi-week human clinical trial to examine both diabetes-related control (in part via reduced blood sugar levels) as well as weight loss following treatment. If design parameters allow, we intend to test, separately, DehydraTECH-GLP-1, as well as a combination of DehydraTECH-CBD with DehydraTECH GLP-1, based on the noteworthy effects of DehydraTECH-CBD evidenced in animal study DIAB-A22-1. Before proceeding with this human evaluation, we hope to have the animal formulation PK and efficacy modelling test results so that we can use the best-performing formulation in the multi-week human clinical trial. Thus, all things being favourable, we expect the multi-week human clinical trial could start near the end of Q2 or sometime in Q3, 2024.</p><p>Execution of the above-described animal study and multi-week human clinical trial will be contingent on raising additional capital necessary to fund doing so. Through these expanded studies, Lexaria hopes to achieve superior PK performance using DehydraTECH-powered GLP-1 drugs which could enable drug delivery via oral capsule at lower costs than current injectables, with reduced side effects and enhanced health benefits. Ultimately, Lexaria's goal in doing so will be to demonstrate advancements worthy of commercial product development and potential pharmaceutical industry strategic partnering interest, for superior performing oral GLP-1 drugs as more viable and attractive alternatives to the injectable format.</p><p><strong>About the Study</strong></p><p>The Study was performed to provide an early-stage indication of whether DehydraTECH processing could improve <i>oral</i> drug delivery characteristics of the GLP-1 drug semaglutide sold as Rybelsus. A single semaglutide dose of 7 mg of the Rybelsus Control was compared to the matching dose of the DehydraTECH GLP-1, swallowed by each subject after an overnight fasting period together with a 50 mL glass of water. The DehydraTECH GLP-1 formulation used in this Study was compound formulated strictly for research purposes. Seven healthy subjects were dosed, four of whom received the DehydraTECH GLP-1, and three of whom received the Control. These seven subjects are expected to return to the Study site in December to be dosed a second time in the reverse order following the "cross-over" design of this Study to ensure that all seven subjects will have been treated with both the Control and DehydraTECH GLP-1 treatments over the course of the two visits.</p><p><strong><u>About GLP-1 Drugs</u></strong>.</p><p>Rybelsus (semaglutide) is <a href="https://pr.report/zvL8jNT9">the only GLP-1 drug approved by the FDA</a> <i>for oral dosing</i> to treat diabetes and weight loss. The FDA has also approved semaglutide marketed as Ozempic® and Wegovy®, <i>administered by injection</i>, to treat diabetes and weight loss. All three of these drugs are owned and manufactured by Novo Nordisk.</p><p>GLP-1 drugs have recently been approved by the FDA for type two diabetes and weight loss management. Weight loss of <a href="https://www.cnbc.com/2023/05/22/pfizer-weight-loss-drug-compares-to-ozempic-by-novo-nordisk.html?&qsearchterm=Ozempic%20and%20Wegovy">between 10 pounds to 33 pounds</a>, or more, has been widely reported. One 68-week study of 667 people reported an <a href="https://pr.report/cGqAF4WS">average loss of 15% of body weight</a>.</p><p>Anecdotal commentary also suggests that some patients are experiencing <a href="https://www.cnbc.com/2023/09/10/ozempic-wegovy-drinking-smoking-what-we-know.html?&qsearchterm=Ozempic%20and%20Wegovy">reduced cravings for alcohol, nicotine and opioids</a> while taking GLP-1 drugs. Other trials are examining their effects on <a href="https://www.cnbc.com/2023/09/07/weight-loss-drugs-wegovy-ozempic-tested-to-treat-addiction-dementia.html?&qsearchterm=Ozempic%20and%20Wegovy">heart disease and even dementia</a> in part because of evidence that GLP-1 drugs may reduce the build-up of the proteins amyloid and tau in the brain, thought to be partly responsible for Alzheimer's disease.</p><p><a href="https://pr.report/acuf91-6">Side effects of GLP-1 drugs</a> vary but can include nausea, vomiting, diarrhea and more. A small number of GLP-1 drugs have already been tested or approved in oral format but <a href="https://pr.report/qv4DkjAV">some studies have reported worse side effects with the oral form</a>. The drugs are also being investigated for their relationship to bone density, muscle loss and more. Because of potential serious side effects, it may be beneficial to treat patients with lower oral doses of the drugs, something that Lexaria's DehydraTECH technology may enable if it can improve the PK performance of GLP-1 drugs through oral capsules.</p><p>Because GLP-1 drugs have experienced FDA approvals as recently as 2021 and 2022, and because the health benefits of this drug class are still being discovered and understood, the potential market size is unknown. Published reports are widely estimating $100 billion in sales per year, by 2030. At least one analyst from Guggenheim Partners published a note on September 12, 2023 in which he explained how "the total addressable market for these so-called incretin drugs <a href="https://pr.report/XayzRubs">could balloon to $150 billion to $200 billion</a>."</p><p><strong>About DehydraTECH</strong></p><p>DehydraTECH is a patented drug delivery formulation and processing platform technology Lexaria has developed and is investigating for a variety of beneficial molecules. DehydraTECH is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria has also developed DehydraTECH formulations for other applications demonstrating superior bio-absorption when administered intraorally and topically.</p><p><strong>About Lexaria Bioscience Corp.</strong></p><p>Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/F23nCDVQ">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#2d445f6d4148554c5f444c4f44425e4e4448434e48034e4240"><span class="__cf_email__" data-cfemail="d0b9a290bcb5a8b1a2b9b1b2b9bfa3b3b9b5beb3b5feb3bfbd">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE: </strong>Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/809947/lexarias-technology-improves-the-oral-performance-of-the-rybelsusr-branded-glp-1-drug-semaglutide-in-human-pilot-study'>https://www.accesswire.com/809947/lexarias-technology-improves-the-oral-performance-of-the-rybelsusr-branded-glp-1-drug-semaglutide-in-human-pilot-study</a><br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2023/11/27/lexarias-technology-improves-the-oral-performance-of-the-rybelsus-branded-glp-1-drug-semaglutide-in-human-pilot-study/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2023/11/27/lexarias-technology-improves-the-oral-performance-of-the-rybelsus-branded-glp-1-drug-semaglutide-in-human-pilot-study/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9010" class="ts-no-featured-content themestek-box-blog-classic post-9010 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">01</div> <div class="ts-blog-classic-dbox-month">Nov</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2023/11/01/lexaria-bioscience-corp-nasdaq-lexx-expands-studies-of-proprietary-platform-in-multibillion-dollar-glp-1-drug-space/">November 1, 2023</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2023/11/01/lexaria-bioscience-corp-nasdaq-lexx-expands-studies-of-proprietary-platform-in-multibillion-dollar-glp-1-drug-space/">Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><link rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p>NEW YORK, Nov. 01, 2023 -- NetworkNewsAudio - <strong>Lexaria Bioscience Corp. (NASDAQ: LEXX) </strong>announces the availability of a broadcast titled, "Can Diabetes, Weight-Loss Drugs Get Even Better?"</p> <p>To hear the AudioPressRelease, please visit: <a href="https://www.globenewswire.com/Tracker?data=2F6ap2lCCF3JmSCEdATS48Wnsv1Mpdwm7HJmrgc5-0Kwo8cAih4NN6Qh9P39nqzd9KbrpJMLfFbplwUrLUDf4pKiE3MSU0SXkJZhgoxRFRwIpKVSHsV4d0lQLRVPx1Gb" rel="nofollow noopener" target="_blank"><u>The NetworkNewsAudio News Podcast</u></a></p> <p>To view the full editorial, please visit: <a href="https://www.globenewswire.com/Tracker?data=t2yLxF0OPZKgsc2et3ktJz4PIZnZjPzrnk_9vEBnI9UYEwuQOSx7TYqXld40xOnDd4arkQuSnDdS9s5QFcmxUQ==" rel="nofollow noopener" target="_blank"><u>https://nnw.fm/q9osg</u></a> </p> <p>It shouldn't be surprising that analysts at Markets and Research estimate the global diabetes drug market at $63.1 billion in 2021 on its way to $82.93 billion in 2027, while the global market for diabetes devices was valued at another $26.1 billion and growing 7.5% annually. Due to the pain and unpleasantness of injections, many diabetes sufferers prefer to treat their condition with drugs rather than devices, if they have the choice. Some of the most popular type 2 diabetes in recent years are GLP-1 (glucagon-like peptide-1) receptor agonists. They work by mimicking the effects of the naturally occurring hormone GLP-1, which helps to regulate blood sugar levels and appetite.</p> <p><strong>Lexaria Bioscience Corp. (NASDAQ: LEXX)</strong> began its DehydraTECH diabetes-related formal studies in 2022 with compelling data highly relevant to diabetes showing positive effects of lowering glucose levels, body weight and triglyceride levels, as well as evidenced increased locomotor activity. With such positive early results, Lexaria is expanding its diabetes study program, including using DehydraTECH for GLP-1 drugs alone and in combination with other molecules. </p> <p><strong>About Lexaria Bioscience Corp.</strong></p> <p>Lexaria's patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. </p> <p>For more information, visit the company's website at <a href="https://www.globenewswire.com/Tracker?data=AspSn1Wl2JbEW-p42qZGFbYpz_7xbGLOsjrZxWo3-lSEJnOTAAtm3HMDY6af4FM_fJ3wz2Lf9-zZ6jxa7odn8ISWdSBc80mLzmy1NC-MNfxV_ehShHNP00AHfyJfEUqR" rel="nofollow noopener" target="_blank"><u>www.LexariaBioscience.com</u></a>.</p> <p><strong>NOTE TO INVESTORS:</strong> The latest news and updates relating to LEXX are available in the company's newsroom at <a href="https://www.globenewswire.com/Tracker?data=t2yLxF0OPZKgsc2et3ktJ-bnUp0VI3B1LAPkC3kkmCxmc7QdaqYTACAnDIycDKZVcA5YortB7usJ-8sRJVV6NA==" rel="nofollow noopener" target="_blank"><u>https://ibn.fm/LEXX</u></a></p> <p><strong>About NetworkNewsWire</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=IAQsnstB-fEegyb0T79cENm_PDB8x2Ssk6xOToyGzywdJtlAw4G_3u9HpiSewx2QVVM2ukxkrFwCZIuL6Eg9QKaHRU7wvem-SG3oKOPsb6A=" rel="nofollow noopener" target="_blank"><u>NetworkNewsWire</u></a> ("NNW") is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the <a href="https://www.globenewswire.com/Tracker?data=2t2_DT2yDwaVtjh-rs2Bcum-eJ_fiVcNIPT3I03o8g6PVtk3so6tyexW-p77Kk821NnfunYKeaAl0JxQrxMPiyH3Qqd4bDH_x23tt-jz52xqVen05fqryYkZDgborHpH5fIV7MZuHoyx30cTI8l57Q==" rel="nofollow noopener" target="_blank"><strong>Dynamic Brand Portfolio</strong></a> @ <a href="https://www.globenewswire.com/Tracker?data=1qCLBY7Rih48rKNoHFMXPjX6qPTf3o6HHr37Fit4b5qPxdcdM7qapfDVgHXqllZUY84-HJdM7fI3VfGl1ulFKQ31SeXsWZWBbh3DP0KDXV4=" rel="nofollow noopener" target="_blank"><strong>IBN</strong></a> that delivers<strong>:</strong> (1) access to a vast network of wire solutions via <a href="https://www.globenewswire.com/Tracker?data=Xnb1aQTeyEP6A6zvMelfj0AfQD6KJzaZr4hwP8lke6lU9-c05ILs2TvQU9mddOjE90tzGKfSReUArGWDH3etPZ7X7ahKNDH1AHxbpV6qmxc=" rel="nofollow noopener" target="_blank"><u>InvestorWire</u></a> to efficiently and effectively reach a myriad of target markets, demographics and diverse industries<strong>;</strong> (2) article and <a href="https://www.globenewswire.com/Tracker?data=DZ1b3UbxhJgwIJP5yDX39_RB1jurIQ96KATrmw3QmIpFpsaSaaQdtitju5CV5b94bCvHtjNPe7NSjlF13JGlnJ_KKo-JvWQqLpXZz7ZZvvRf9mNF3fRo9Pg6hU0nx5Dc5gLqrlFfQevnLx5LOP7X75kkYJuh3HLngK22uJHy2B3Bi3tlHHnIF9DnVjEj9F9xo2xnQBPAm6B05h8iSjke_AKGG-fEZJa2SCrToWHo_Y0=" rel="nofollow noopener" target="_blank"><u>editorial syndication to 5,000+ outlets</u></a><strong>;</strong> (3) <a href="https://www.globenewswire.com/Tracker?data=Hhwx5O8N5yobpE0NS3H8sV5WQ1tAn0qEeoiONc4_6uInLCiL99SJ4z7JGLAB1BzlHLFeMucT-1wo16QlbKYfTE_zKfbD2OnzHkKlWs6gqLVBFpM8_heZHmhMxzFEes0qgkDKGFQXrZAG5JU5BIxyCPv8k1S8Kwns5d25E02lsnSvL6aqsyZEIJ2Qy_HgQwYx" rel="nofollow noopener" target="_blank"><u>press release enhancement</u></a> to ensure maximum impact<strong>;</strong> (4) <a href="https://www.globenewswire.com/Tracker?data=bgMkZ3QJDLdnUvuhLu3HQx6Y1gA5ObHaRjO5551N9FewjS2TPJYdCgTB-SF6WDeNq4rwX7GqujgTWB5bUO8OtJ17x8CzMAXamf2RYsk6hxCiasfXbf_3vBYSNsNPGAkka8LT3XwOjpaQefq5BO8QKQ==" rel="nofollow noopener" target="_blank"><u>social media distribution</u></a> via IBN to millions of social media followers<strong>;</strong> and (5) a full array of tailored <a href="https://www.globenewswire.com/Tracker?data=5klUqSheUxUPoR0xIcMTe8U57sQF3n7hcxF0BCf17Fyn--hbY32g1o6M4ty0DqZURWmG4HAum3UTooAK34-ll33MocUe7Db1Um8boQcVRE2vZTKkovItTKQ9eVA9Katz40LsMRCDRObogB7y9F0CzA==" rel="nofollow noopener" target="_blank"><u>corporate communications solutions</u></a>. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.</p> <p>For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=t2yLxF0OPZKgsc2et3ktJ5_0OYGosevB236a7a7wrMcE_6UVkCiTEnutfxHzTUtZTIdGSDt7YTIIJppRkQrLS8D_zyd1OE-0BRuc8h6E9Bn8LWLiMPtG_3_w3nQP8Fd6" rel="nofollow noopener" target="_blank"><u>https://www.NetworkNewsWire.com</u></a></p> <p>Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: <a href="https://www.globenewswire.com/Tracker?data=t2yLxF0OPZKgsc2et3ktJ5_0OYGosevB236a7a7wrMe3o5VbBfKJ517ik8H6S6y9UI_i2bX67zorjz2cC1ANN4zGu1DaFzsxs5j4nqoJ6eqgpzwc8OsdgDJRNR8s7pajq6NU4tMCxCq4zZ9F6gTMww==" rel="nofollow noopener" target="_blank"><u>https://www.NetworkNewsWire.com/Disclaimer</u></a></p> <p>NetworkNewsWire<br />New York, NY<br /> <a href="https://www.globenewswire.com/Tracker?data=93WBIZRh1ckGVfKPj8iiym8PSs0ezu6M0j5JRPGiB1zip0shUEgEVfwlNe5ELqkQLt4wU-6nwxiCE6w6iWkQG6uhaWHshR6-9mWpK3K7mZU=" rel="nofollow noopener" target="_blank"><u>www.NetworkNewsWire.com</u></a><br /> 212.418.1217 Office<br /> <a href="https://www.globenewswire.com/Tracker?data=qyF7Hln_TM7XlUlpk9oIBAkSW9yCKTB3P5olOKQkvIB8DzNmBE9qyP2FHDARXzYnp8CAGe_yT6wlcnf9h2ydbO6SBDZsXBqHgPiZKsM2MOxUHeUYzV-ppvLL7VLgrMPa" rel="nofollow noopener" target="_blank"><u><span class="__cf_email__" data-cfemail="c782a3aeb3a8b58789a2b3b0a8b5ac89a2b0b490aeb5a2e9a4a8aa">[email protected]</span></u></a></p> <p>NetworkNewsWire is powered by <a href="https://www.globenewswire.com/Tracker?data=izi54tDiFjuVni7gaPhX-583dpRJ-pnaQzUVyk3AroP3xIBP8bKST0U9TYeWCKbBqhLo_IVQDc7PudmE99ftTFNv3aGj2boAtiAb3mAYEt4=" rel="nofollow noopener" target="_blank"><u>IBN</u></a></p> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODk3MDMwMCM1OTAzNDg4IzUwMDAzMzc1Mw==" /> <br /><img src="https://ml.globenewswire.com/media/YjZjYTc4NTYtYWZmNS00MTc3LWE0ZDktYzI4ZjQ1Mzk2YmQzLTUwMDAzMzc1Mw==/tiny/Lexaria-Bioscience-Corp-.png" /><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/e37ba76b-1ed6-4de4-b482-a904e4fce250"><img src="https://ml.globenewswire.com/media/e37ba76b-1ed6-4de4-b482-a904e4fce250/small/lexaria-jpg.jpg" border="0" width="150" height="78" alt="Primary Logo" /></a></p></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2023/11/01/lexaria-bioscience-corp-nasdaq-lexx-expands-studies-of-proprietary-platform-in-multibillion-dollar-glp-1-drug-space/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2023/11/01/lexaria-bioscience-corp-nasdaq-lexx-expands-studies-of-proprietary-platform-in-multibillion-dollar-glp-1-drug-space/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9011" class="ts-no-featured-content themestek-box-blog-classic post-9011 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">31</div> <div class="ts-blog-classic-dbox-month">Oct</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2023/10/31/lexaria-bioscience-corp-nasdaq-lexx-evaluating-proprietary-drug-delivery-platform-for-improved-efficacy-of-glp-1-drugs/">October 31, 2023</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2023/10/31/lexaria-bioscience-corp-nasdaq-lexx-evaluating-proprietary-drug-delivery-platform-for-improved-efficacy-of-glp-1-drugs/">Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><link rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p>NEW YORK, Oct. 31, 2023 -- via <a href="https://www.globenewswire.com/Tracker?data=bUdyqjViHmvwGeQkGWl9GPeDLgoqt_lqpRwe_pPk7M34zPr8iXV8IOYLRntAolJXS9FElaJmhsYvocfA2E372Q==" rel="nofollow noopener" target="_blank"><u>InvestorWire</u></a> - <strong>Lexaria Bioscience Corp. (NASDAQ: LEXX) </strong>today announces its placement in an editorial published by <a href="https://www.globenewswire.com/Tracker?data=i3WnL17No7AThCi86ddbiYz2moEJuaZp9-MaUJbkVKX3vKoWNE8oANVNL7N6vFWV2CUWaQDwxxfHBLpd7LosLOmQnR_exLeRdk4yQpXv-Zg=" rel="nofollow noopener" target="_blank"><u>NetworkNewsWire</u></a> ("NNW"), one of 60+ brands within the <a href="https://www.globenewswire.com/Tracker?data=UjxWTww-uhl-NzlTd5iiJNzY41E9YsiPXme2W3suNTTt9pTrCyFVfYz0bIMlLdcYnskX6UNvwyA5w5kAyRkVWlxiim4wBrDjXsmxskl6AxGBpUn8mKEqtlQnqdYzFYa99BC6pcqaHnYI6f15vphj3Q==" rel="nofollow noopener" target="_blank"><b><u>Dynamic Brand Portfolio</u></b></a> @ <a href="https://www.globenewswire.com/Tracker?data=xwKT9ArkxAVPR0C-D124Nz9UPV9D3m7aDONcnVPVtybDXny7AEQJZ-VFTPEwAbtOlH7hDL2wKp92jszMRRzQGQ==" rel="nofollow noopener" target="_blank"><b><u>IBN</u></b></a> (<a href="https://www.globenewswire.com/Tracker?data=bUdyqjViHmvwGeQkGWl9GL26zxLGYRMGwv0wfr10fxQxycfgIN_WWgKRBHYTP6kD1ANy-imQmp1SJyyKpjs3tU7Ka_xWBuvD6MQGHbBIyU8=" rel="nofollow noopener" target="_blank"><u>InvestorBrandNetwork</u></a><u>)</u>, a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.</p> <p>To view the full publication, "Can Diabetes, Weight-Loss Drugs Get Even Better?",<br />please visit: <a href="https://www.globenewswire.com/Tracker?data=Q7b6PYi39i3mUfresZ1xPOV3v6ilAXn1uddjwHBZtksnEptmf7z2AkemOcADQxUDO3qToGSzutNO3iv43TCD_Q==" rel="nofollow noopener" target="_blank"><u>https://nnw.fm/q9osg</u></a> </p> <p>The prestigious "New England Journal of Medicine" recently published results of a large study of 2,539 adults wherein weight loss of 49 to 52 pounds was a common outcome. With more than 37 million Americans suffering from diabetes, and with obesity at epidemic levels, it's little wonder that millions of people are singing their praises of the new class of drugs responsible for these outrageously positive outcomes. GLP-1 agonists are a class of medications that mainly help manage blood sugar (glucose) levels in people with type 2 diabetes but are also helping treat obesity. Seems everyone is excited about controlling blood sugar and easily losing weight. </p> <p>But there may be an even better avenue to increased effectiveness and better outcomes. <strong>Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug-delivery platforms, began diabetes-related formal studies last year with its DehydraTECH(TM) platform, which showed reduced blood-sugar levels and lowered body weight. With such encouraging early results, Lexaria is planning to launch new human and animal studies to examine whether DehydraTECH processing can make GLP-1 drugs such as semaglutide even better.</strong> </p> <p><strong>About Lexaria Bioscience Corp.</strong></p> <p>Lexaria's patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. </p> <p>For more information, visit the company's website at <a href="https://www.globenewswire.com/Tracker?data=ZEvn0Rkrlyfo65xii1KpP_3Il7uBjUA6TSPta9YsAa2Mvt1W2VoNsH91FyLCctvLxG9oNvHyNG-U3cTZYuMW8UTztcFgFSPhym0wNcoMr1xb0nskeACP9hXRINMzLWOu" rel="nofollow noopener" target="_blank"><u>www.LexariaBioscience.com</u></a>.</p> <p><strong>NOTE TO INVESTORS:</strong> The latest news and updates relating to LEXX are available in the company's newsroom at <a href="https://www.globenewswire.com/Tracker?data=Q7b6PYi39i3mUfresZ1xPGepEwDemikeQvN2xERDKUo0RTYsuxkxRbS1qsdXmnosautE91b4OuXbsuibvmZi9A==" rel="nofollow noopener" target="_blank"><u>https://ibn.fm/LEXX</u></a></p> <p><strong>About NetworkNewsWire</strong></p> <p><a href="https://www.globenewswire.com/Tracker?data=i3WnL17No7AThCi86ddbicJGffQEeTQDhK6IP6L27VDjaHvebmkeRcexHfeEGU2YuaU4qezXr_RqP9IG1PSW2e8iYA7DxQvPAInlfhZfX88=" rel="nofollow noopener" target="_blank"><u>NetworkNewsWire</u></a> ("NNW") is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the <a href="https://www.globenewswire.com/Tracker?data=UjxWTww-uhl-NzlTd5iiJNzY41E9YsiPXme2W3suNTT2cmkiUNTHaUR8BEIi6YoXEIqPq6zxwkHZVlRsdcsOZKVd3V-YzTLs13JHAmr9yK6iXLOnLVPt75ts--8eOf236VNpxVRfjrUI-IpW2xY9Rg==" rel="nofollow noopener" target="_blank"><strong>Dynamic Brand Portfolio</strong></a> @ <a href="https://www.globenewswire.com/Tracker?data=g1243mcqmdKN1K39_71EOLb30FD2TQrsJJk3tlouGPuxa5I428PB0Sot-LtsItQTsyjyErJIYXkYU9vxR9-KfhaUNZhEHL7gZtCV2TobMoQ=" rel="nofollow noopener" target="_blank"><strong>IBN</strong></a> that delivers<strong>:</strong> (1) access to a vast network of wire solutions via <a href="https://www.globenewswire.com/Tracker?data=bUdyqjViHmvwGeQkGWl9GJT0S9nWZjZ8ATL8lwlwe_ChutCt09YtiM8l9Vz3BOPiT3cbT1njIGApLqFMQ2jvT28W5oZoFw0qAbfqYPm-oC8=" rel="nofollow noopener" target="_blank"><u>InvestorWire</u></a> to efficiently and effectively reach a myriad of target markets, demographics and diverse industries<strong>;</strong> (2) article and <a href="https://www.globenewswire.com/Tracker?data=1ci-xrV1n5zJrr6-WFe5Ri0T0b781Vb9KDVZsztIAP4pGHBs27GAAJgZpNLGV3_7M0uJFNBoP7sKhEjQm8wzcIEoEtvk52G3QHaru8sHA2M1TyQj4nVVVfzgXxJJ_ZU5RxARCPcXfT-kphLTFzcPSEcUdZHbd4gwf3Au8BWLqS_U5hYRylb2pCsiqVqRM6cT1lP6D-c4_5d-43B7_nDZPW8RCGsC-ZvA0ezlQg9A0eA=" rel="nofollow noopener" target="_blank"><u>editorial syndication to 5,000+ outlets</u></a><strong>;</strong> (3) <a href="https://www.globenewswire.com/Tracker?data=3-vraRRYx4qaH9s2AXu8feBk3_b4jVaST4T6RYE2STb0qSY0esRyEtmLrrz4dZ4ocSm1bnGRVhYf_cGEJncI_AoQV5rUM_OeP1i3eBjpkSmC8pnAK1cM8yWwf_f3aExaInGIo1JqdgOZ_6RQFnsuR5QpH1azeNOreWyXTYUpxgMtdUfz78Lzf9s3bBU3Tk8F" rel="nofollow noopener" target="_blank"><u>press release enhancement</u></a> to ensure maximum impact<strong>;</strong> (4) <a href="https://www.globenewswire.com/Tracker?data=c_2iKi1K674SLfHGX17YOlsdTAOLoIWEGfLgtiVmWGrYtXTtEZXlPQIRk2HOZPn07xVZy8OrZL-ztqrHdEFSnTr-KrO4bWUHx_WyfR58MJE35ES_wTqVuJYvusb4XOh9wgjWHyyj4w__GPtd83kdiA==" rel="nofollow noopener" target="_blank"><u>social media distribution</u></a> via IBN to millions of social media followers<strong>;</strong> and (5) a full array of tailored <a href="https://www.globenewswire.com/Tracker?data=c_D4ImaBHOX-GrRMQfBWRZ7igSdLHlrxGLjuwf33yjEOUgrAOJNVgF71DUAfueY0L31RFiHQzRc0DHi6OPo_2o4HBtzAvMpl7aJ513pqKvpBOYEjAz53pRjHxlZQV9ae3_XzjmCWCdIoCVEymFnnBw==" rel="nofollow noopener" target="_blank"><u>corporate communications solutions</u></a>. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.</p> <p>For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=Q7b6PYi39i3mUfresZ1xPNQXrxVzY1zPuPFBSFaHWGk5ovRu-eiv2A4aLLXiHGla4d8y_8tCFEqDAEIQU3-gEJmHxw_UK-0bUXphMw67WdxszRHEAQffLGG5Mmm6xNo1" rel="nofollow noopener" target="_blank"><u>https://www.NetworkNewsWire.com</u></a></p> <p>Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: <a href="https://www.globenewswire.com/Tracker?data=Q7b6PYi39i3mUfresZ1xPNQXrxVzY1zPuPFBSFaHWGm-LhLDZFQcBHVbNxoXgiuhx6Zr4dIVr1R7ueB-GMxSYVBX8eVjcSjw8iqagX90rA6BpKlkhd-yOMqJ6ZzGMGtxc2_-RjyFd_Rch8riaaJCXQ==" rel="nofollow noopener" target="_blank"><u>https://www.NetworkNewsWire.com/Disclaimer</u></a></p> <p>NetworkNewsWire<br />New York, NY<br /> <a href="https://www.globenewswire.com/Tracker?data=e1J3saiwaRfS_Jz8f1WDw8cnrJChMKVn2tIgoyRi650ReDy6dV68J47JT7UjU4y1-oG4VM9r9MC0WgOmZBLLIgLX2-FnTRkZnzdK3OpmHfw=" rel="nofollow noopener" target="_blank"><u>www.NetworkNewsWire.com</u></a><br /> 212.418.1217 Office<br /> <a href="https://www.globenewswire.com/Tracker?data=_wvl9yfP6Rlb3TiIdxRZCgxyvucw8DAKcbZ32z6Js-YnjfEWFkvaXds5lIvPklkw9OjQlM4ukld3kXzyWe4uai9AnCOgT21zN2lr7PHbuIR_sNjAt_09z1p6i0Ie-92x" rel="nofollow noopener" target="_blank"><u><span class="__cf_email__" data-cfemail="2a6f4e435e45586a644f5e5d455841644f5d597d43584f04494547">[email protected]</span></u></a></p> <p>NetworkNewsWire is powered by <a href="https://www.globenewswire.com/Tracker?data=0J8V1epfBmxb_P49RZO1BT4DauS9nruIhIZmPa77QsU_34FfUCH2AE9DnG6PEzYD-ycIgPYPddfOD_v-8UzkkB2C48YYt24xSaJRQ7OCxFI=" rel="nofollow noopener" target="_blank"><u>IBN</u></a></p> <img class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=ODk2OTI5OCM1OTAwNjY4IzUwMDAzMzc1Mw==" /> <br /><img src="https://ml.globenewswire.com/media/MTViNWQ5OTItMGQ2OS00ZWY2LTg2YTAtOGM0YzJiMGQxMmQ5LTUwMDAzMzc1Mw==/tiny/Lexaria-Bioscience-Corp-.png" /><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/e37ba76b-1ed6-4de4-b482-a904e4fce250"><img src="https://ml.globenewswire.com/media/e37ba76b-1ed6-4de4-b482-a904e4fce250/small/lexaria-jpg.jpg" border="0" width="150" height="78" alt="Primary Logo" /></a></p></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2023/10/31/lexaria-bioscience-corp-nasdaq-lexx-evaluating-proprietary-drug-delivery-platform-for-improved-efficacy-of-glp-1-drugs/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2023/10/31/lexaria-bioscience-corp-nasdaq-lexx-evaluating-proprietary-drug-delivery-platform-for-improved-efficacy-of-glp-1-drugs/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9048" class="ts-no-featured-content themestek-box-blog-classic post-9048 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">13</div> <div class="ts-blog-classic-dbox-month">Oct</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2023/10/13/lexaria-enters-new-global-exclusive-collaboration-and-license-agreement-with-sulfosyn/">October 13, 2023</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2023/10/13/lexaria-enters-new-global-exclusive-collaboration-and-license-agreement-with-sulfosyn/">Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><ul><li><i><strong>Global exclusivity for all non-pharmaceutical applications of DehydraTECH-sulforaphane has been awarded</strong></i></li><li><i><strong>Minimum ongoing payments, royalties and manufacturing revenues part of the agreement</strong></i></li></ul><p><strong>KELOWNA, BC / October 13, 2023 /</strong> Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has granted a new global, exclusive license to use DehydraTECH technology to SulfoSyn Limited ("SulfoSyn").</p><p>The exclusive license granted to SulfoSyn is for all non-pharmaceutical uses of sulforaphane world-wide, including SulfoSyn's ability to sub-license these rights. These non-pharmaceutical uses include but are not limited to supplements, additives, foods, dietary ingredients, and more. An up-front cash payment has already been received, minimum future payments have been agreed to, and ongoing royalty payments will be generated when they are in excess of the minimum payments.</p><p>As part of a broader agreement between the two companies, Lexaria is also being contracted to perform certain DehydraTECH-related manufacturing operations at its US partner facility on behalf of SulfoSyn for an initial term of 2 years. These manufacturing operations are expected to result in an increase in revenue to Lexaria, the amount of which cannot be forecasted at this time.</p><p>Beginning in late 2022, Lexaria and SulfoSyn began exploring the applicability of DehydraTECH upon sulforaphane. In extensive testing since, it has been determined that DehydraTECH confers certain superior qualities upon the sulforaphane molecule that are of commercial interest.</p><p>Sulforaphane is a sulphur-rich composite molecule commonly found in vegetables such as broccoli, cabbage and kale. According to <a href="https://pr.report/5ayfe7qP">this study published at the National Library of Medicine</a>, sulforaphane has been shown to exhibit anti-inflammatory, antioxidant, antimicrobial and even antiaging qualities.</p><p><strong>About Lexaria Bioscience Corp.</strong><br />Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/E36RejPv">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong><br />This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong><br /><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#a5ccd7e5c9c0ddc4d7ccc4c7cccad6c6ccc0cbc6c08bc6cac8"><span class="__cf_email__" data-cfemail="c2abb082aea7baa3b0aba3a0abadb1a1aba7aca1a7eca1adaf">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE: </strong>Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/792561/lexaria-enters-new-global-exclusive-collaboration-and-license-agreement-with-sulfosyn'>https://www.accesswire.com/792561/lexaria-enters-new-global-exclusive-collaboration-and-license-agreement-with-sulfosyn</a><br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2023/10/13/lexaria-enters-new-global-exclusive-collaboration-and-license-agreement-with-sulfosyn/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2023/10/13/lexaria-enters-new-global-exclusive-collaboration-and-license-agreement-with-sulfosyn/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9050" class="ts-no-featured-content themestek-box-blog-classic post-9050 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">12</div> <div class="ts-blog-classic-dbox-month">Oct</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2023/10/12/lexaria-granted-two-new-patents-in-canada/">October 12, 2023</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2023/10/12/lexaria-granted-two-new-patents-in-canada/">Lexaria Granted Two New Patents in Canada</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><ul><li><i><strong>Lexaria now holds 37 granted patents world-wide</strong></i></li><li><i><strong>Potential application in treating nicotine addiction</strong></i></li></ul><p><strong>KELOWNA, BC / October 12, 2023 /</strong> Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has been granted two new patents by the Canadian Intellectual Property Office ("CIPO"), increasing Lexaria's complete patent portfolio to 37 granted patents.</p><p>Canadian Patent #2,984,917, <i>"Stable Ready-to-drink Beverage Compositions Comprising Lipophilic Active Agents"</i> was granted on September 26, 2023, and expires December 1, 2036. This patent recognizes Lexaria's innovations in delivering lipophilic (fat-based) active drugs and active molecules suspended in a water-based format. Lexaria's DehydraTECH technology can be used in both dry formats such as capsules and pills, as well as in liquid formats such as drops, tinctures and also beverages including consumer beverages. This is Lexaria's 6th granted patent in its patent family #3.</p><p>Canadian patent #3,111,082, <i>"Lipohilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof"</i> was granted on August 29, 2023, and expires on September 13, 2039. This patent recognizes Lexaria's innovations in infusing tobacco leaves directly with drugs or active molecules such as nicotine with or without cannabinoids for potential applications such as treating nicotine addiction. This is Lexaria's 1st granted patent in its patent family #14.</p><p>Lexaria has also filed for international patent protection for DehydraTECH-powered oral-nicotine following the <a href="https://pr.report/XUN1B3rQ">earlier 2023 award</a> of this patent class in the USA.</p><p><strong>About Lexaria Bioscience Corp.</strong></p><p>Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 37 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/y6jJmdci">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#630a11230f061b02110a02010a0c10000a060d00064d000c0e"><span class="__cf_email__" data-cfemail="93fae1d3fff6ebf2e1faf2f1fafce0f0faf6fdf0f6bdf0fcfe">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/792191/lexaria-granted-two-new-patents-in-canada'>https://www.accesswire.com/792191/lexaria-granted-two-new-patents-in-canada</a><br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2023/10/12/lexaria-granted-two-new-patents-in-canada/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2023/10/12/lexaria-granted-two-new-patents-in-canada/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9049" class="ts-no-featured-content themestek-box-blog-classic post-9049 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">29</div> <div class="ts-blog-classic-dbox-month">Sep</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2023/09/29/lexaria-announces-pricing-of-1-6-million-registered-direct-offering/">September 29, 2023</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2023/09/29/lexaria-announces-pricing-of-1-6-million-registered-direct-offering/">Lexaria Announces Pricing of $1.6 Million Registered Direct Offering</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><strong>KELOWNA, BC / September 29, 2023 /</strong> Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to purchase 1,618,330 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering. In a concurrent private placement, the Company also agreed to issue and sell to the investor warrants to purchase up to 1,618,330 shares of common stock. The combined effective offering price for each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrant is $0.97. The warrants will become exercisable six months from issuance, expire five and a half years from the issuance date and have an exercise price of $0.97 per share.</p><p>The gross proceeds to the Company from the registered direct offering and concurrent private placement are estimated to be approximately $1.6 million before deducting the placement agent's fees and other estimated offering expenses payable by the Company. The offering is expected to close on or about October 3, 2023, subject to the satisfaction of customary closing conditions.</p><p>Maxim Group LLC is acting as the sole placement agent in connection with the offering.</p><p>The shares of common stock (or pre-funded warrants in lieu thereof) are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333- 262402), which was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on February 4, 2022. The offering of shares of common stock (or pre-funded warrants in lieu thereof) will be made only by means of a prospectus supplement that forms a part of such registration statement. The warrants to be issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws.</p><p>This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock and pre-funded warrants will be filed by the Company with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at <a href="https://pr.report/iWU4-1GB">www.sec.gov</a> or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at <a href="/cdn-cgi/l/email-protection#74070d1a101d171500113419150c1d191306045a171b19"><span class="__cf_email__" data-cfemail="27545e49434e44465342674a465f4e4a4055570944484a">[email protected]</span></a> or telephone at (212) 895-3500.</p><p><strong>About Lexaria Bioscience Corp.</strong><br />Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 36 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/7ESZ9xYo">www.lexariabioscience.com</a>.</p><p><strong>Forward-Looking Statements</strong><br />This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong><br /><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#9cf5eedcf0f9e4fdeef5fdfef5f3effff5f9f2fff9b2fff3f1"><span class="__cf_email__" data-cfemail="563f24163a332e37243f37343f3925353f333835337835393b">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/788575/lexaria-announces-pricing-of-16-million-registered-direct-offering'>https://www.accesswire.com/788575/lexaria-announces-pricing-of-16-million-registered-direct-offering</a><br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2023/09/29/lexaria-announces-pricing-of-1-6-million-registered-direct-offering/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2023/09/29/lexaria-announces-pricing-of-1-6-million-registered-direct-offering/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9051" class="ts-no-featured-content themestek-box-blog-classic post-9051 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">21</div> <div class="ts-blog-classic-dbox-month">Sep</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2023/09/21/lexaria-to-evaluate-impact-of-dehydratech-on-oral-performance-of-glp-1-drugs-used-in-products-such-as-ozempic-wegovy-and-rybelsus-alone-or-together-with-dehydratech-cbd/">September 21, 2023</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2023/09/21/lexaria-to-evaluate-impact-of-dehydratech-on-oral-performance-of-glp-1-drugs-used-in-products-such-as-ozempic-wegovy-and-rybelsus-alone-or-together-with-dehydratech-cbd/">Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><i><strong>DehydraTECH-powered GLP-1 drugs will be evaluated for potential improvements such as:</strong></i></p><ul><li><i>Reduced side effects;</i></li><li><i>Enhanced weight loss;</i></li><li><i>Improved health outcomes for diabetes and other conditions;</i></li><li><i>Improved oral bioavailability;</i></li><li><i>Reduced cost.</i></li></ul><p style="text-align:justify"><strong>KELOWNA, BC / September 21, 2023 / </strong>Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces its intention to launch new human and animal studies to examine DehydraTECH™-processed glucagon-like peptide-1 ("GLP-1") drugs such as, but not limited to, semaglutide sold under Novo Nordisk's brand names Ozempic®, Wegovy® and Rybelsus®, for purposes of improved bioavailability, cost-effectiveness, tolerability, weight loss potential, management of diabetes and other health conditions.</p><p style="text-align:justify">Through these studies, Lexaria hopes to achieve superior pharmacokinetic ("PK") performance using DehydraTECH-powered GLP-1 drugs which could enable drug delivery via oral capsule at lower costs than current injectables, with reduced side effects and enhanced health benefits.</p><p style="text-align:justify">This is a significant expansion of Lexaria's ongoing and planned diabetes study program to examine its patented DehydraTECH-CBD for diabetes control in humans. The Company now intends to evaluate this alongside and together with DehydraTECH-processed GLP-1 agents. Program design has already commenced, and initial study work will begin as soon as possible.</p><p style="text-align:justify">Lexaria has demonstrated in many previous R&D programs, including five human clinical studies, that DehydraTECH can greatly improve the PK performance of many orally administered drugs into the bloodstream, such as certain antiviral drugs, estradiol, PDE-5 Inhibitors, cannabinoids and more. Like many of these agents, GLP-1 drugs also exhibit low oral bioavailability without the use of absorption enhancement technology, such as Lexaria's DehydraTECH. Lexaria has also previously shown in animal studies that its patented DehydraTECH-CBD lowered body weight over a sustained dosing period by 7%, and also lowered blood sugar and triglyceride levels.</p><p style="text-align:justify">The Company has also demonstrated that specific customized DehydraTECH oral capsule formulations can achieve remarkable improvements in PK performance. For example, the particular DehydraTECH-CBD formulation that was used in its recently completed <a href="https://pr.report/w9ycLFVP">DIAB-A22-1</a> diabetes study demonstrated almost a 3-fold improvement in drug delivery into blood than the differentiated DehydraTECH-CBD formulation that was used in Lexaria's HYPER-H21-4 hypertension study that, itself, <a href="https://pr.report/Inmqy9Qf">demonstrated significantly better PK</a> performance and effectiveness <a href="https://pr.report/dUSF1kDP">than pharmaceutical-grade CBD industry comparators like Epidiolex</a>®.</p><p style="text-align:justify"><strong><u>About GLP-1 Drugs</u></strong>.</p><p style="text-align:justify">GLP-1 drugs have recently been approved by the Food and Drug Administration ("FDA") for type two diabetes and weight loss management. Weight loss of <a href="https://www.cnbc.com/2023/05/22/pfizer-weight-loss-drug-compares-to-ozempic-by-novo-nordisk.html?&qsearchterm=Ozempic%20and%20Wegovy">between 10 pounds to 33 pounds</a>, or more, has been widely reported. One 68-week study of 667 people reported an <a href="https://pr.report/RWp1sThN">average loss of 15% of body weight</a>.</p><p style="text-align:justify">Widely reported anecdotal commentary is also suggesting that some patients are experiencing <a href="https://www.cnbc.com/2023/09/10/ozempic-wegovy-drinking-smoking-what-we-know.html?&qsearchterm=Ozempic%20and%20Wegovy">reduced cravings for alcohol, nicotine and opioids</a> while taking GLP-1 drugs. Other trials are examining their effects on <a href="https://www.cnbc.com/2023/09/07/weight-loss-drugs-wegovy-ozempic-tested-to-treat-addiction-dementia.html?&qsearchterm=Ozempic%20and%20Wegovy">heart disease and even dementia</a> in part because of evidence that GLP-1 drugs may reduce the build-up of the proteins amyloid and tau in the brain, thought to be partly responsible for Alzheimer's disease.</p><p style="text-align:justify"><a href="https://pr.report/9s0mQP7O">Side effects of the GLP-1 drugs</a> vary but can include nausea, vomiting, diarrhea and more. A small number of GLP-1 drugs have already been approved in oral format but <a href="https://pr.report/jr2qf48m">some studies have reported worse side effects with the oral form</a>. The drugs are also being investigated for their relationship to bone density, muscle loss and more. Because of potential serious side effects, it may be beneficial to treat patients with lower oral doses of the drugs, something that Lexaria's DehydraTECH technology may enable if it can improve the PK performance of GLP-1 drugs through oral capsules.</p><p style="text-align:justify">Although the GLP-1 drugs are effective at controlling diabetes and promoting weight loss, they are expensive, and the benefits often reverse if the patient stops taking the drug. Typical <a href="https://pr.report/kdhFHc9p">non-insured costs of US$900/month</a> or more are common. If DehydraTECH improves the PK performance of oral GLP-1 drugs it could potentially result in cost savings for the patient through lower doses.</p><p style="text-align:justify">Because GLP-1 drugs have experienced FDA approvals as recently as 2021 and 2022, and because the health benefits of this drug class are still being discovered and understood, the potential market size is still unknown. Published reports are widely estimating $100 billion in sales per year, by 2030. At least one analyst from Guggenheim Partners published a note on September 12 in which he explained how "the total addressable market for these so-called incretin drugs <a href="https://pr.report/37aT5wzg">could balloon to $150 billion to $200 billion</a>."</p><p style="text-align:justify"><strong><u>About Lexaria's Diabetes Study Program.</u></strong></p><p style="text-align:justify">Lexaria began its DehydraTECH diabetes-related formal studies in 2022. On <a href="https://pr.report/QGjWLAvZ">March 2, 2023</a> and <a href="https://pr.report/Hq9Dc3Fo">June 16, 2023</a> Lexaria announced that in pre-clinical diabetes study <a href="https://pr.report/wNBheF27">DIAB-A22-1</a> in obese diabetic-conditioned animals, DehydraTECH-CBD achieved each of the following:</p><ul><li style="text-align:justify">Lowered blood glucose levels by 19.9% (p<0.05)</li><li style="text-align:justify">Lowered overall body weight by 7% sustained over 8 weeks</li><li style="text-align:justify">Increased locomotor activity (p<0.05)</li><li style="text-align:justify">Lowered triglyceride levels by more than 25% (p<0.007)</li><li style="text-align:justify">Lowered blood urea nitrogen levels by 27.9% (p<0.001)</li></ul><p>On August 2, 2023 <a href="https://pr.report/gTy0vu7V">Lexaria announced its intention</a> to study weight loss and diabetes control in a human population using DehydraTECH-CBD.</p><p>Lexaria's goals within its diabetes study program have significantly expanded and now include the concept of applying DehydraTECH technology, individually, to each of CBD and GLP-1 drug(s), but also to potentially utilize a combination of drugs that includes both a GLP-1 component and DehydraTECH-CBD, together. At this time, no other company in the world is utilizing DehdyraTECH technology relative to GLP-1 drugs.</p><p>DehydraTECH-CBD's ability to reduce blood sugar levels in animals is extremely encouraging and warrants additional investigation. According to the Center for Disease Control, <a href="https://www.cdc.gov/diabetes/managing/manage-blood-sugar.html#:~:text=It's%20important%20to%20keep%20your,improve%20your%20energy%20and%20mood.">managing your blood sugar levels</a> is important to avoid diabetes-related conditions such as vision loss, heart disease, and kidney disease. Limited research, mostly in animal studies, indicates that without DehydraTECH's noteworthy performance enhancements, <a href="https://diabetes.org/healthy-living/medication-treatments/cbd-diabetes#:~:text=There's%20a%20lot%20of%20hype,people%20with%20type%202%20diabetes.">generic CBD might be ineffective in controlling blood sugars</a>.</p><p><strong>About DehydraTECH</strong></p><p>DehydraTECH is a patented drug delivery formulation and processing platform technology Lexaria has developed and is investigating for a variety of beneficial molecules. DehydraTECH is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria has also developed DehydraTECH formulations for other applications demonstrating superior bio-absorption when administered intraorally and topically.</p><p><strong>About Lexaria Bioscience Corp.</strong></p><p>Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 36 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/XNTHfPWU">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br /><a href="/cdn-cgi/l/email-protection#fd948fbd9198859c8f949c9f94928e9e9498939e98d39e9290"><span class="__cf_email__" data-cfemail="90f9e2d0fcf5e8f1e2f9f1f2f9ffe3f3f9f5fef3f5bef3fffd">[email protected]</span></a><br />Phone: 250-765-6424, ext 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/786174/lexaria-to-evaluate-impact-of-dehydratech-on-oral-performance-of-glp-1-drugs-used-in-products-such-as-ozempic-wegovy-and-rybelsus-alone-or-together-with-dehydratech-cbd'>https://www.accesswire.com/786174/lexaria-to-evaluate-impact-of-dehydratech-on-oral-performance-of-glp-1-drugs-used-in-products-such-as-ozempic-wegovy-and-rybelsus-alone-or-together-with-dehydratech-cbd</a><br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2023/09/21/lexaria-to-evaluate-impact-of-dehydratech-on-oral-performance-of-glp-1-drugs-used-in-products-such-as-ozempic-wegovy-and-rybelsus-alone-or-together-with-dehydratech-cbd/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2023/09/21/lexaria-to-evaluate-impact-of-dehydratech-on-oral-performance-of-glp-1-drugs-used-in-products-such-as-ozempic-wegovy-and-rybelsus-alone-or-together-with-dehydratech-cbd/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <article id="post-9052" class="ts-no-featured-content themestek-box-blog-classic post-9052 post type-post status-publish format-standard hentry category-press-releases" > <div class="ts-blog-classic-featured-wrapper"> <div class="ts-blog-classic-datebox-overlay"> <div class="ts-blog-classic-dbox-date">30</div> <div class="ts-blog-classic-dbox-month">Aug</div> </div> </div> <div class="ts-blog-classic-box-content ">  <div class="ts-featured-meta-wrapper ts-featured-overlay"> <div class="ts-blog-post-date"> <span class="ts-meta-line"><span class="screen-reader-text ts-hide">Date </span> <i class="ts-labtechco-icon-clock"></i> <a href="https://lexariabioscience.com/2023/08/30/lexaria-provides-update-on-investigational-new-drug-application-progress/">August 30, 2023</a></span> </div> <div class="ts-blog-post-cat ts-blog-post-cat-above-title"> <span class="ts-meta-line cat-links"><span class="screen-reader-text ts-hide">Categories </span> <i class="ts-labtechco-icon-category"></i> <a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a></span> </div> <div class="themestek-box-title"><h4><a href="https://lexariabioscience.com/2023/08/30/lexaria-provides-update-on-investigational-new-drug-application-progress/">Lexaria Provides Update on Investigational New Drug Application Progress</a></h4></div> </div>  <div class="entry-content"> <div class="themestek-box-desc-text"><div class="b2iNewsItemBodyDiv"><p><strong>KELOWNA, BC / August 30, 2023 /</strong> Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is providing this update on the status of the Company's anticipated submission of an Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its planned U.S. Phase 1b Hypertension Clinical Trial designated as HYPER-H23-1.</p><p>As previously reported, work that was mostly under Lexaria's control such as batch manufacturing of DehydraTECH™-processed cannabidiol and placebo materials necessary for the IND application filing was completed earlier this year, followed by analytical release and ongoing stability testing.</p><p>In parallel, compilation of the large set of documentation necessary for inclusion in the IND filing has been progressing on time by the Company and its service providers. However, work that is outside of Lexaria's control, namely the provision of required documentation by one of Lexaria's material suppliers related to their analytical and stability testing of their material, has been delayed. Accordingly, Lexaria is not in a position to submit the IND package to the FDA for their review and consideration until these delays have been cured by the supplier.</p><p>Lexaria is in communication with its material supplier to provide their required information as soon as possible but, as at the current date, we have not received the results nor an estimated time of receipt for same. Lexaria continues to finalize the IND application so that the Company is in a position to file with the FDA as soon as possible following receipt of the outstanding information and will provide updated details regarding the status of its IND application filing as they become available.</p><p><strong>Background and Medical/Market Rationale</strong></p><p>Lexaria's five previous human clinical studies of DehydraTECH-CBD in hypertension conducted from 2018 through 2022, which were not conducted under FDA-registration but are integral to successful filing and review of its planned IND submission, were carried out in an aggregate total of 134 healthy and hypertensive persons. These foundational studies evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens, and also produced zero serious adverse events; suggesting that DehydraTECH-CBD has the potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics.</p><p>Lexaria is aware of only a handful of <a href="https://pr.report/Kk9erzGE">other published research studies</a>, mostly in young, healthy and normotensive volunteers, that have investigated whether a sustained decrease in resting blood pressure is possible following multiple weeks of oral CBD dosing; none of which have been successful in achieving this. DehydraTECH-CBD is currently unique in its evidenced superior power to reduce blood pressure over other oral CBD formulations.</p><p>Findings from Lexaria's latest study HYPER-H21-4 <a href="https://pr.report/V2rKke6-">demonstrated a potentially novel mechanism of action</a> of DehydraTECH-CBD in reducing blood pressure which may be explained, at least in part, by its interaction with the human sympatho-chromaffin system via catestatin modulation as detailed in the<a href="https://pr.report/aND8kVW7">peer-reviewed and published</a> respected journal, "<i>Biomedicine and Pharmacotherapy</i>". This is significant because the FDA has previously laid out <a href="https://pr.report/DGgrCMOv">clear guidelines for sponsors</a> who seek to develop new anti-hypertensive drugs, specifically defining the need for medications that offer novel and complementary modes of action. Data gathered from study HYPER-H21-4 suggested that DehydraTECH-CBD had the potential to offer <a href="https://pr.report/L2aIknPr">additive blood pressure reduction benefits</a> on top of any degree of improvements that standard of care medications achieved for patients prior to DehydraTECH-CBD dosing.</p><p><strong>About Planned Clinical Trial HYPER-H23-1</strong></p><p>Clinical trial HYPER-H23-1 is entitled ‘<i>A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension'</i>. The primary objective of the trial will be to evaluate safety and tolerability in hypertensive patients, and secondary objectives will include efficacy evaluation in reducing blood pressure together with detailed pharmacokinetic testing.</p><p>All clinical, laboratory and analysis procedures for study HYPER-H23-1 are to be performed entirely by U.S.-based, third-party independent contract service providers.</p><p><strong>About DehydraTECH</strong></p><p>DehydraTECH is a patented drug delivery formulation and processing platform technology Lexaria has developed and is investigating for a variety of beneficial molecules. DehydraTECH is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue, which Lexaria believes to be of particular importance for centrally active compounds. Lexaria has also developed DehydraTECH formulations for other applications demonstrating superior bio-absorption when administered intraorally and topically.</p><p><strong>About Lexaria Bioscience Corp.</strong></p><p>Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 35 patents granted and many patents pending worldwide. For more information, please visit <a href="https://pr.report/dukvgAof">www.lexariabioscience.com</a>.</p><p><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></p><p>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</p><p><strong>INVESTOR CONTACT:</strong></p><p><strong>George Jurcic - Head of Investor Relations</strong><br><a href="/cdn-cgi/l/email-protection#1f766d5f737a677e6d767e7d76706c7c767a717c7a317c7072"><span class="__cf_email__" data-cfemail="5b32291b373e233a29323a3932342838323e35383e75383436">[email protected]</span></a><br>Phone: 250-765-6424, ext 202</p><p><strong>SOURCE: </strong>Lexaria Bioscience Corp.</p><br><br>View source version on accesswire.com: <br><a href='https://www.accesswire.com/778356/Lexaria-Provides-Update-on-Investigational-New-Drug-Application-Progress'>https://www.accesswire.com/778356/Lexaria-Provides-Update-on-Investigational-New-Drug-Application-Progress</a><br><br></div></div> <div class="themestek-blog-classic-footer-readmore"> <div class="themestek-blogbox-footer-left"><a href="https://lexariabioscience.com/2023/08/30/lexaria-provides-update-on-investigational-new-drug-application-progress/">Read More</a></div> </div> <div class="ts-footer-meta-wrapper"> <span class="ts-footer-meta-line-w ts-footer-meta-line-comments"> <a href="https://lexariabioscience.com/2023/08/30/lexaria-provides-update-on-investigational-new-drug-application-progress/"> <i class="ts-labtechco-icon-comment-1"></i> <span class="comments"> 0 Comments </span> </a> </span> <span class="ts-footer-meta-line-w ts-footer-meta-line-author"> <span class="author vcard"> <span class="screen-reader-text ts-hide">Author </span> <a class="url fn n" href="https://lexariabioscience.com/author/mmcdonald/"><i class="ts-labtechco-icon-user"></i> mmcdonald</a> </span> </span> </div> </div> </div> </article> <div class="clearfix"></div><div class="themestek-pagination"><span aria-current="page" class="page-numbers current">1</span> <a class="page-numbers" href="https://lexariabioscience.com/2023/page/2/">2</a> <a class="page-numbers" href="https://lexariabioscience.com/2023/page/3/">3</a> <a class="next page-numbers" href="https://lexariabioscience.com/2023/page/2/"><span class="ts-hide ts-pagination-text ts-pagination-text-next">Next page</span> <i class="ts-labtechco-icon-arrow-right"></i></a></div> </main> </div> <aside id="sidebar-right" class="widget-area col-md-3 col-lg-3 col-xs-12 sidebar"> <aside id="search-2" class="widget-even widget-6 widget widget_search"><form role="search" method="get" class="search-form" action="https://lexariabioscience.com/"> <label> <span class="screen-reader-text">Search for:</span> <input type="search" class="search-field" placeholder="Search …" value="" name="s" /> </label> <input type="submit" class="search-submit" value="Search" /> </form></aside><aside id="categories-2" class="widget-odd widget-7 widget widget_categories"><h3 class="widget-title">Categories</h3> <ul> <li class="cat-item cat-item-2"><a href="https://lexariabioscience.com/category/chemistry-laboratories/">Chemistry</a> <span>1</span> </li> <li class="cat-item cat-item-3"><a href="https://lexariabioscience.com/category/forensic-science/">Forensic science</a> <span>3</span> </li> <li class="cat-item cat-item-4"><a href="https://lexariabioscience.com/category/gemological-laboratories/">Gemological</a> <span>3</span> </li> <li class="cat-item cat-item-37"><a href="https://lexariabioscience.com/category/press-releases/">Press Releases</a> <span>157</span> </li> <li class="cat-item cat-item-5"><a href="https://lexariabioscience.com/category/scientific-laboratory/">Scientific</a> <span>3</span> </li> <li class="cat-item cat-item-1"><a href="https://lexariabioscience.com/category/uncategorized/">Uncategorized</a> <span>1</span> </li> </ul> </aside> <aside id="themestek-recent-posts-2" class="widget-even widget-8 widget themestek_widget_recent_entries"> <h3 class="widget-title">Recent Posts</h3> <ul class="ts-recent-post-list"> <li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2024/11/20/all-study-groups-using-dehydratech-processing-outperform-rybelsus-in-body-weight-control-in-lexarias-12-week-glp-1-diabetes-animal-study/">ALL Study Groups using DehydraTECH Processing Outperform Rybelsus® in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study</a><span class="post-date">November 20, 2024</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2024/11/14/lexaria-signs-contract-for-new-dehydratech-glp-1-biodistribution-study/">Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study</a><span class="post-date">November 14, 2024</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2024/11/13/ethics-board-approval-granted-for-lexarias-12-week-phase-1b-dehydratech-glp-1-study-in-diabetes-and-weight-loss/">Ethics Board Approval Granted for Lexaria’s 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss</a><span class="post-date">November 13, 2024</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2024/11/07/lexaria-updates-fast-moving-glp-1-arms-race-developments/">Lexaria Updates Fast-Moving GLP-1 ‘Arm’s Race’ Developments</a><span class="post-date">November 7, 2024</span></li><li class="ts-recent-post-list-li"><a href="https://lexariabioscience.com/2024/10/24/positive-partial-12-week-blood-sugar-results-from-lexarias-glp-1-diabetes-animal-study/">Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study</a><span class="post-date">October 24, 2024</span></li> </ul> </aside> <aside id="tag_cloud-2" class="widget-odd widget-9 widget widget_tag_cloud"><h3 class="widget-title">Tags</h3><div class="tagcloud"><a href="https://lexariabioscience.com/tag/biochemistry-research/" class="tag-cloud-link tag-link-6 tag-link-position-1" style="font-size: 22pt;" aria-label="Biochemistry research (3 items)">Biochemistry research</a> <a href="https://lexariabioscience.com/tag/chemistry/" class="tag-cloud-link tag-link-7 tag-link-position-2" style="font-size: 22pt;" aria-label="Chemistry (3 items)">Chemistry</a> <a href="https://lexariabioscience.com/tag/equipment/" class="tag-cloud-link tag-link-8 tag-link-position-3" style="font-size: 8pt;" aria-label="equipment‎ (2 items)">equipment‎</a> <a href="https://lexariabioscience.com/tag/medical/" class="tag-cloud-link tag-link-9 tag-link-position-4" style="font-size: 8pt;" aria-label="Medical (2 items)">Medical</a> <a href="https://lexariabioscience.com/tag/physics/" class="tag-cloud-link tag-link-10 tag-link-position-5" style="font-size: 22pt;" aria-label="Physics (3 items)">Physics</a> <a href="https://lexariabioscience.com/tag/scientific-research/" class="tag-cloud-link tag-link-11 tag-link-position-6" style="font-size: 22pt;" aria-label="scientific research (3 items)">scientific research</a></div> </aside><aside id="archives-3" class="widget-even widget-10 widget widget_archive"><h3 class="widget-title">Archives</h3> <ul> <li><a href='https://lexariabioscience.com/2024/11/'>November 2024</a></li> <li><a href='https://lexariabioscience.com/2024/10/'>October 2024</a></li> <li><a href='https://lexariabioscience.com/2024/09/'>September 2024</a></li> <li><a href='https://lexariabioscience.com/2024/08/'>August 2024</a></li> <li><a href='https://lexariabioscience.com/2024/07/'>July 2024</a></li> <li><a href='https://lexariabioscience.com/2024/06/'>June 2024</a></li> <li><a href='https://lexariabioscience.com/2024/05/'>May 2024</a></li> <li><a href='https://lexariabioscience.com/2024/04/'>April 2024</a></li> <li><a href='https://lexariabioscience.com/2024/03/'>March 2024</a></li> <li><a href='https://lexariabioscience.com/2024/02/'>February 2024</a></li> <li><a href='https://lexariabioscience.com/2024/01/'>January 2024</a></li> <li><a href='https://lexariabioscience.com/2023/12/'>December 2023</a></li> <li><a href='https://lexariabioscience.com/2023/11/'>November 2023</a></li> <li><a href='https://lexariabioscience.com/2023/10/'>October 2023</a></li> <li><a href='https://lexariabioscience.com/2023/09/'>September 2023</a></li> <li><a href='https://lexariabioscience.com/2023/08/'>August 2023</a></li> <li><a href='https://lexariabioscience.com/2023/07/'>July 2023</a></li> <li><a href='https://lexariabioscience.com/2023/06/'>June 2023</a></li> <li><a href='https://lexariabioscience.com/2023/05/'>May 2023</a></li> <li><a href='https://lexariabioscience.com/2023/04/'>April 2023</a></li> <li><a href='https://lexariabioscience.com/2023/03/'>March 2023</a></li> <li><a href='https://lexariabioscience.com/2023/02/'>February 2023</a></li> <li><a href='https://lexariabioscience.com/2023/01/'>January 2023</a></li> <li><a href='https://lexariabioscience.com/2022/12/'>December 2022</a></li> <li><a href='https://lexariabioscience.com/2022/11/'>November 2022</a></li> <li><a href='https://lexariabioscience.com/2022/10/'>October 2022</a></li> <li><a href='https://lexariabioscience.com/2022/09/'>September 2022</a></li> <li><a href='https://lexariabioscience.com/2022/08/'>August 2022</a></li> <li><a href='https://lexariabioscience.com/2022/07/'>July 2022</a></li> <li><a href='https://lexariabioscience.com/2022/06/'>June 2022</a></li> <li><a href='https://lexariabioscience.com/2022/05/'>May 2022</a></li> <li><a href='https://lexariabioscience.com/2022/04/'>April 2022</a></li> <li><a href='https://lexariabioscience.com/2022/03/'>March 2022</a></li> <li><a href='https://lexariabioscience.com/2022/02/'>February 2022</a></li> <li><a href='https://lexariabioscience.com/2022/01/'>January 2022</a></li> <li><a href='https://lexariabioscience.com/2021/12/'>December 2021</a></li> <li><a href='https://lexariabioscience.com/2021/11/'>November 2021</a></li> <li><a href='https://lexariabioscience.com/2021/10/'>October 2021</a></li> <li><a href='https://lexariabioscience.com/2021/09/'>September 2021</a></li> <li><a href='https://lexariabioscience.com/2021/07/'>July 2021</a></li> <li><a href='https://lexariabioscience.com/2021/06/'>June 2021</a></li> <li><a href='https://lexariabioscience.com/2021/05/'>May 2021</a></li> <li><a href='https://lexariabioscience.com/2021/04/'>April 2021</a></li> <li><a href='https://lexariabioscience.com/2021/03/'>March 2021</a></li> <li><a href='https://lexariabioscience.com/2021/02/'>February 2021</a></li> <li><a href='https://lexariabioscience.com/2021/01/'>January 2021</a></li> <li><a href='https://lexariabioscience.com/2018/08/'>August 2018</a></li> <li><a href='https://lexariabioscience.com/2018/02/'>February 2018</a></li> <li><a href='https://lexariabioscience.com/2018/01/'>January 2018</a></li> <li><a href='https://lexariabioscience.com/2017/09/'>September 2017</a></li> <li><a href='https://lexariabioscience.com/2017/08/'>August 2017</a></li> <li><a href='https://lexariabioscience.com/2014/12/'>December 2014</a></li> </ul> </aside></aside> </div> </div> </div> <footer id="colophon" class="site-footer "> <div class="footer_inner_wrapper footer ts-bg ts-bgcolor-grey ts-bgimage-no"> <div class="site-footer-bg-layer ts-bg-layer"></div> <div class="site-footer-w"> <div class="footer-rows"> <div class="footer-rows-inner"> <div id="first-footer" class="sidebar-container first-footer ts-bg ts-bgcolor-grey ts-textcolor-dark ts-bgimage-no" role="complementary"> <div class="first-footer-bg-layer ts-bg-layer"></div> <div class="container"> <div class="first-footer-inner"> <div class="row multi-columns-row"> <div class="widget-area col-xs-12 col-sm-4 col-md-4 col-lg-4 first-widget-area"> <aside id="block-11" class="widget-odd widget-5 widget widget_block widget_media_image"> <figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" src="https://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png" alt="" class="wp-image-7760" width="180" height="95" srcset="https://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB.png 418w, https://lexariabioscience.com/wp-content/uploads/2022/03/Lexaria_Bioscience_Logo_Dark_WEB-300x158.png 300w" sizes="auto, (max-width: 180px) 100vw, 180px" /></figure> </aside><aside id="block-2" class="widget-even widget-6 widget widget_block widget_text"> <p>Lexaria Bioscience Corp. (NASDAQ:LEXX) has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules.</p> </aside> </div> <div class="widget-area col-xs-12 col-sm-4 col-md-4 col-lg-4 first-widget-area"> <aside id="block-35" class="widget-odd widget-5 widget widget_block widget_text"> <p><a href="tel:+12507656424">250.765.6424</a><br><a href="/cdn-cgi/l/email-protection#a1c8cfc7cee1cdc4d9c0d3c8c0c3c8ced2c2c8c4cfc2c48fc2cecc"><span class="__cf_email__" data-cfemail="f0999e969fb09c95889182999192999f839399959e9395de939f9d">[email protected]</span></a></p> </aside><aside id="block-37" class="widget-even widget-6 widget widget_block widget_text"> <p><b>Canadian Operations</b><br>#100-740 McCurdy Road<br>Kelowna, BC, V1X2P7<br><br><strong>US Operations</strong><br>105 Peach State Court, Suite A<br>Tyrone, GA 30290</p> </aside><aside id="block-31" class="widget-odd widget-7 widget widget_block widget_text"> <p><a href="https://lexariabioscience.com/privacy-policy/">Privacy Policy</a></p> </aside><aside id="block-13" class="widget-even widget-8 widget widget_block"><p><ul id="" class="cnss-social-icon " style="text-align:left;"><li class="cn-fa-facebook cn-fa-icon " style="display:inline-block;"><a class="" target="_blank" href="https://www.facebook.com/lexariabioscience" title="facebook" style="width:28px;height:28px;padding:5px 0;margin:6px;color: #ffffff;border-radius: 0%;"><i title="facebook" style="font-size:18px;" class="fab fa-facebook"></i></a></li><li class="cn-fa-twitter cn-fa-icon " style="display:inline-block;"><a class="" target="_blank" href="https://twitter.com/lexariabiocorp" title="twitter" style="width:28px;height:28px;padding:5px 0;margin:6px;color: #ffffff;border-radius: 0%;"><i title="twitter" style="font-size:18px;" class="fab fa-twitter"></i></a></li><li class="cn-fa-linkedin cn-fa-icon " style="display:inline-block;"><a class="" target="_blank" href="https://www.linkedin.com/company/lexaria-bioscience/" title="linkedin" style="width:28px;height:28px;padding:5px 0;margin:6px;color: #ffffff;border-radius: 0%;"><i title="linkedin" style="font-size:18px;" class="fab fa-linkedin"></i></a></li></ul></p> </aside> </div> <div class="widget-area col-xs-12 col-sm-4 col-md-4 col-lg-4 first-widget-area"> <aside id="block-10" class="widget-even widget-2 widget widget_block widget_text"> <p><strong>General Disclaimer:</strong><br>No statement in this web site has been evaluated by the Food and Drug Administration (FDA). Furthermore, none of the statements in this web site should be construed as dispensing medical advice or making claims regarding the cure of diseases…<br><br><a href="https://lexariabioscience.com/general-disclaimer/">Read More</a></p> </aside> </div> </div> </div> </div> </div> </div> </div> <div id="bottom-footer-text" class="bottom-footer-text ts-bottom-footer-text site-info ts-bg ts-bgcolor-transparent ts-textcolor-dark ts-bgimage-no"> <div class="bottom-footer-bg-layer ts-bg-layer"></div> <div class="container"> <div class="bottom-footer-inner"> <div class="row multi-columns-row"> <div class="col-xs-12 col-sm-12 ts-footer2-left "> Copyright © 2024 <a href="https://lexariabioscience.com">Lexaria Bioscience</a>. All rights reserved. </div> </div> </div> </div> </div> </div> </div> </footer> </div> </div>  <a id="totop" href="#top"><i class="ts-labtechco-icon-angle-up"></i></a> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script> window.RS_MODULES = window.RS_MODULES || {}; window.RS_MODULES.modules = window.RS_MODULES.modules || {}; window.RS_MODULES.waiting = window.RS_MODULES.waiting || []; window.RS_MODULES.defered = true; window.RS_MODULES.moduleWaiting = window.RS_MODULES.moduleWaiting || {}; window.RS_MODULES.type = 'compiled'; </script> <script>(function(){var s=document.createElement('script');e = !document.body ? document.querySelector('head'):document.body;s.src='https://acsbapp.com/apps/app/dist/js/app.js';s.defer=true;s.onload=function(){acsbJS.init({ statementLink : '', feedbackLink : '', footerHtml : '', hideMobile : false, hideTrigger : false, language : 'en', position : 'right', leadColor : '#3a5dae', triggerColor : '#3a5dae', triggerRadius : '50%', triggerPositionX : 'right', triggerPositionY : 'top', triggerIcon : 'people', triggerSize : 'medium', triggerOffsetX : 15, triggerOffsetY : 50, mobile : { triggerSize : 'small', triggerPositionX : 'left', triggerPositionY : 'center', triggerOffsetX : 0, triggerOffsetY : 0, triggerRadius : '50%' } }); }; e.appendChild(s);}());</script> <script> var _paq = _paq || []; _paq.push(['trackPageView']); (function () { var u = "https://stats1.wpmudev.com/"; _paq.push(['setTrackerUrl', u + 'track/']); _paq.push(['setSiteId', '102684']); var d = document, g = d.createElement('script'), s = d.getElementsByTagName('script')[0]; g.type = 'text/javascript'; g.async = true; g.defer = true; g.src = 'https://stats.wpmucdn.com/analytics.js'; s.parentNode.insertBefore(g, s); })(); </script> <script> jQuery('#popmake-8310').find('.ts-vc_btn3').click(function() { document.cookie = "pum-8310=true;"; }); </script><link rel='stylesheet' id='rs-plugin-settings-css' href='https://lexariabioscience.com/wp-content/plugins/revslider/public/assets/css/rs6.css?ver=6.5.15' media='all' /> <style id='rs-plugin-settings-inline-css'> #rs-demo-id {} </style> <script src="https://lexariabioscience.com/wp-includes/js/jquery/ui/core.min.js?ver=1.13.3" id="jquery-ui-core-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/jquery/ui/mouse.min.js?ver=1.13.3" id="jquery-ui-mouse-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/jquery/ui/sortable.min.js?ver=1.13.3" id="jquery-ui-sortable-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/dist/hooks.min.js?ver=4d63a3d491d11ffd8ac6" id="wp-hooks-js"></script> <script src="https://lexariabioscience.com/wp-includes/js/dist/i18n.min.js?ver=5e580eb46a90c2b997e6" id="wp-i18n-js"></script> <script id="wp-i18n-js-after"> /* <![CDATA[ */ wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); /* ]]> */ </script> <script src="https://lexariabioscience.com/wp-content/plugins/contact-form-7/includes/swv/js/index.js?ver=6.0" id="swv-js"></script> <script id="contact-form-7-js-before"> /* <![CDATA[ */ var wpcf7 = { "api": { "root": "https:\/\/lexariabioscience.com\/wp-json\/", "namespace": "contact-form-7\/v1" } }; /* ]]> */ </script> <script src="https://lexariabioscience.com/wp-content/plugins/contact-form-7/includes/js/index.js?ver=6.0" id="contact-form-7-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/revslider/public/assets/js/rbtools.min.js?ver=6.5.15" defer async id="tp-tools-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/revslider/public/assets/js/rs6.min.js?ver=6.5.15" defer async id="revmin-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/perfect-scrollbar/perfect-scrollbar.jquery.min.js?ver=6.7.1" id="perfect-scrollbar-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/select2/select2.min.js?ver=6.7.1" id="ts-select2-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/node_modules/isotope-layout/dist/isotope.pkgd.min.js?ver=7.7.2" id="isotope-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/jquery-mousewheel/jquery.mousewheel.min.js?ver=6.7.1" id="jquery-mousewheel-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/node_modules/flexslider/jquery.flexslider-min.js?ver=7.7.2" id="flexslider-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/sticky-kit/jquery.sticky-kit.min.js?ver=6.7.1" id="sticky-kit-js"></script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/libraries/slick/slick.min.js?ver=6.7.1" id="slick-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/lib/vendor/prettyphoto/js/jquery.prettyPhoto.min.js?ver=7.7.2" id="prettyphoto-js"></script> <script src="https://lexariabioscience.com/wp-content/plugins/js_composer/assets/js/dist/js_composer_front.min.js?ver=7.7.2" id="wpb_composer_front_js-js"></script> <script id="labtechco-script-js-extra"> /* <![CDATA[ */ var ts_labtechco_js_vars = {"ts_breakpoint":"1200","ajaxurl":"https:\/\/lexariabioscience.com\/wp-admin\/admin-ajax.php"}; /* ]]> */ </script> <script src="https://lexariabioscience.com/wp-content/themes/labtechco/js/scripts.min.js?ver=1.0" id="labtechco-script-js"></script> <script></script> <script> jQuery(document).ready(function() { var target = document.querySelector('.site-header-menu-inner'); if (target) { var observer = new MutationObserver(function(mutationsList) { mutationsList.forEach(function(mutation) { if (mutation.type === 'attributes' && mutation.attributeName === 'class') { if (jQuery(target).hasClass('is_stuck')) { // console.log('.is_stuck class added'); jQuery('.investor-menu').addClass('sticky-nav'); } else { // console.log('.is_stuck class removed'); jQuery('.investor-menu').removeClass('sticky-nav'); } } }); }); observer.observe(target, { attributes: true }); } });</script>   <script> // JavaScript to toggle the menu document.addEventListener('DOMContentLoaded', function() { var hamburger = document.querySelector('.hamburger'); var menu = document.querySelector('.investor-menu ul.menu'); hamburger.addEventListener('click', function() { menu.classList.toggle('active'); }); }); </script>  </body> </html>